<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106339</article-id><article-id pub-id-type="doi">10.7554/eLife.106339</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Knight</surname><given-names>Hannah Riley</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8903-9985</contrib-id><email>hrknight@uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Marie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3373-6618</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Kannan</surname><given-names>Nisha</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2173-5340</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Hannah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2146-8764</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Main</surname><given-names>Hailey</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0004-0460-8512</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Azcue</surname><given-names>Emily</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1088-8854</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Esser-Kahn</surname><given-names>Aaron</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1273-0951</contrib-id><email>aesserkahn@uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Pritzker School of Molecular Engineering, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Biological Sciences Division, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>Department of Chemistry, University of Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Domínguez-Andrés</surname><given-names>Jorge</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Nijmegen Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028qa3n13</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>07</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e106339</elocation-id><history><date date-type="received" iso-8601-date="2025-03-03"><day>03</day><month>03</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-01"><day>01</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement>© 2025, Knight et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Knight et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106339-v1.pdf"/><abstract><p>Trained immunity presents a unique target for modulating the immune response against infectious and non-infectious threats to human health. To address the unmet need for training-targeted therapies, we explore bioengineering methods to answer research questions and address clinical applications. Current challenges in trained immunity include self-propagating autoinflammatory disease, a lack of controllable cell and tissue specificity, and the unintentional induction of training by known drugs and diseases. The bioengineering tools discussed in this review (nanotherapeutics, biomechanical modulation, cellular engineering, and machine learning) could address these challenges by providing additional avenues to modulate and interrogate trained immunity. The preferential activation of peripheral or central training has not yet been achieved and could be accessed using nanoparticle systems. Targeted delivery of training stimuli using nanocarriers can enrich the response in various cell and organ systems, while also selectively activating peripheral training in the local tissues or central trained immunity in bone marrow progenitor cells. Beyond chemical- or pathogen-based activation of training, force-based cues, such as interaction with mechanoreceptors, can induce trained phenotypes in many cell types. Mechanotransduction influences immune cell activation, motility, and morphology and could be harnessed as a tool to modulate training states in next-generation therapies. For known genetic and epigenetic mediators of trained immunity, cellular engineering could precisely activate or deactivate programs of training. Genetic engineering could be particularly useful in generating trained cell-based therapies like chimeric antigen receptor (CAR) macrophages. Finally, machine learning models, which are rapidly transforming biomedical research, can be employed to identify signatures of trained immunity in pre-existing datasets. They can also predict protein targets for previously identified inducers of trained immunity by modeling drug-protein or protein-protein interactions in silico. By harnessing the modular techniques of bioengineering for applications in trained immunity, training-based therapies can be more efficiently translated into clinical practice.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>bioengineering</kwd><kwd>trained immunity</kwd><kwd>nanotherapeutics</kwd><kwd>biomechanics</kwd><kwd>cellular engineering</kwd><kwd>machine learning</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>NIAID</institution></institution-wrap></funding-source><award-id>75N93019C00041</award-id><principal-award-recipient><name><surname>Esser-Kahn</surname><given-names>Aaron</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>NSF GRFP</institution></institution-wrap></funding-source><award-id>NSF 2140001</award-id><principal-award-recipient><name><surname>Knight</surname><given-names>Hannah Riley</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>NIH MSTP</institution></institution-wrap></funding-source><award-id>NIH T32GM150375</award-id><principal-award-recipient><name><surname>Taylor</surname><given-names>Hannah</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Bioengineering is a complex and often nebulous concept encompassing many overlapping scientific disciplines (<xref ref-type="bibr" rid="bib135">Nature, 2023</xref>). Fundamentally, bioengineering is the application of engineering concepts to biological systems, either for the generation of a product or the enhancement of the biological system <italic>as</italic> the product (<xref ref-type="bibr" rid="bib81">Ideker et al., 2006</xref>; <xref ref-type="bibr" rid="bib36">Citron and Nerem, 2004</xref>). The earliest mentions of bio- or biomedical engineering in scientific literature appeared toward the end of the Second World War, but it would not join departments of engineering schools in earnest until the 1970s (<xref ref-type="bibr" rid="bib76">Hoagland, 1944</xref><xref ref-type="bibr" rid="bib137">Nerem, 1997</xref>). By then, developments in medical diagnostics, imaging, and molecular biology allowed for the precise study and manipulation of biological systems required for such a ‘systems engineering’ approach. Scientists had the tools to introduce precise, well-controlled perturbations and measure their effects. This shift led to the practical application of bioengineering: the development of tools, technologies, delivery systems, and measurement methods to understand and manipulate biology. Today, these experimental approaches range from quantum-based biosensors to genome editing to patient-derived organoids (<xref ref-type="bibr" rid="bib90">Kalkal et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Cox et al., 2015</xref>; <xref ref-type="bibr" rid="bib185">Too et al., 2021</xref>).</p><p>Bioengineering is not limited to experimental techniques in research labs. It has also found its way into clinical practice, with the first nanoparticle-based therapeutic, Doxil, gaining FDA approval in 1995 (<xref ref-type="bibr" rid="bib16">Barenholz, 2012</xref>). Cell and gene therapies, which were once considered science fiction are now widely accepted, including autologous stem cell therapies for a variety of conditions, chimeric antigen receptor T cells (CAR-Ts) for blood cancers, and gene therapies for single-gene disorders such as sickle cell disease (<xref ref-type="bibr" rid="bib106">Leonard and Tisdale, 2024</xref>; <xref ref-type="bibr" rid="bib101">Larson and Maus, 2021</xref>; <xref ref-type="bibr" rid="bib193">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib105">Lee et al., 2024</xref>; <xref ref-type="bibr" rid="bib207">Zhang and Cheng, 2023</xref>). Despite the massive organizational and financial investments in bioengineering, too little attention has been paid to the innate immune system. Innate immune cells were considered primordial, only responding to evolutionarily conserved patterns and lacking the ability to learn from their experiences. This perception changed with the introduction of trained immunity by Mihai Netea and colleagues in 2011 (<xref ref-type="bibr" rid="bib138">Netea et al., 2011</xref>).</p><p>Trained immunity is defined as the epigenetic and metabolic reprogramming of innate immune cells. Until recently, inducers of trained immunity have been limited to endogenous signaling molecules and pathogen-derived sources that directly activate pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). However, non-inflammatory drugs and drug-like compounds identified by high-throughput screening induce training in vitro and in vivo (<xref ref-type="bibr" rid="bib97">Knight et al., 2024</xref>; <xref ref-type="bibr" rid="bib5">Ajit et al., 2024</xref>). This expansion of known inducers of trained immunity offers alternative methods to induce training without initial immune activation. In addition, new work has further suggested that training is not a universal state but is rather stimulus-specific, resulting in different effector responses determined by initial activation (<xref ref-type="bibr" rid="bib147">O’Farrell et al., 2025</xref>). Together, these new insights highlight the importance of tailoring training based on the desired outcome.</p><p>Our motivation for this article is twofold. First, we seek to introduce bioengineering techniques and perspectives to those studying the mechanistic biology of trained immunity. Second, we aim to promote trained immunity as a therapeutic target among bioengineers. Applying bioengineering approaches, including targeted delivery, biomechanical modulation, genetic engineering, and machine learning, can further expand the repertoire of trained immunity inducers and extend the reach of its clinical applications (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib131">Mulder et al., 2019</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Proposed bioengineering approaches to understanding and applying trained immunity.</title><p>This figure was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/kait51k">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106339-fig1-v1.tif"/></fig><p>Here, we explore the current state of bioengineered trained immunity and suggest avenues for future research and innovation. We will begin by defining central and peripheral training and outlining the key challenges in activating one or more modes of training. Then, we explore passive and active targeting approaches, including nanotherapeutics, as a potential solution. Next, mechanotransduction and cellular engineering approaches are discussed as both research and therapeutic methods. Finally, we propose the use of machine learning to identify new drug and protein targets and extract training-like signatures from preexisting clinical and epidemiologic datasets. We hope to encourage the translation of trained immunity from bench to bedside through the application of bioengineering techniques.</p><sec id="s1-1"><title>Central vs. peripheral trained immunity</title><p>Central trained immunity is the epigenetic and metabolic reprogramming of the long-lived progenitor cells of the bone marrow, hematopoietic stem cells (HSCs) (<xref ref-type="bibr" rid="bib93">Kaufmann et al., 2018</xref>). Peripheral trained immunity is the immunometabolic reprogramming of mature, terminally differentiated, tissue-resident cells such as alveolar macrophages and skin epithelial cells (<xref ref-type="bibr" rid="bib64">Geller et al., 2022</xref>). While there is interest in inducing central and peripheral trained immunity either independently or in combination, the challenge of disentangling these two types of training has not yet been overcome. Furthermore, without the ability to selectively activate one type of training or the other, it is difficult to determine the contribution of each type of training to the immune response.</p><sec id="s1-1-1"><title>Maladaptive central training in hematopoietic stem cells: a target for training suppression</title><p>Depending on the original stimulus, training has been observed to endure as long as one year (<xref ref-type="bibr" rid="bib141">Netea et al., 2020</xref>). Induction of central training in HSCs occurs in the bone marrow and allows for epigenetic reprogramming, which is passed down to daughter cells that eventually differentiate into trained effector cells (e.g. monocytes and macrophages) (<xref ref-type="bibr" rid="bib139">Netea et al., 2016</xref>). The mechanisms by which HSCs in the bone marrow niche acquire trained immunity is being extensively investigated, with many insights stemming from studies using systemic delivery of Bacille Calmette-Guérin (BCG) and β-glucan (<xref ref-type="bibr" rid="bib93">Kaufmann et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">de Laval et al., 2020</xref>; <xref ref-type="bibr" rid="bib124">Mills et al., 2024</xref>; <xref ref-type="bibr" rid="bib129">Moorlag et al., 2020</xref>).</p><p>Both β-glucan and BCG reprogram myeloid progenitors in the bone marrow (<xref ref-type="bibr" rid="bib30">Chavakis et al., 2019</xref>). In mice, central training by β-glucan is driven by perturbations in glycolysis, cholesterol biosynthesis, NLRP3 inflammasome activation, and IL-1β or granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling (<xref ref-type="bibr" rid="bib128">Mitroulis et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Kalafati et al., 2020</xref>). In systemic BCG vaccination, <xref ref-type="bibr" rid="bib93">Kaufmann et al., 2018</xref> have demonstrated reprogramming of HSCs towards myelopoiesis, which leads to protective trained immunity in a mouse model of tuberculosis (<xref ref-type="bibr" rid="bib93">Kaufmann et al., 2018</xref>). The memory-like function of HSCs can explain how short-lived immune cells such as monocytes are imprinted with durable epigenetic marks.</p><p>Persistent activation of immune cells from central trained immunity may drive pathology of chronic inflammatory diseases such as diabetes, atherosclerosis, and myocardial infarction (<xref ref-type="bibr" rid="bib124">Mills et al., 2024</xref>; <xref ref-type="bibr" rid="bib48">Edgar et al., 2021</xref>; <xref ref-type="bibr" rid="bib189">van der Heijden et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Dong et al., 2024</xref>). Overactive immune responses can damage healthy tissues and worsen disease progression, while also increasing susceptibility to other diseases, including cancer (<xref ref-type="bibr" rid="bib98">Koelwyn et al., 2020</xref>).</p><p>The NLRP3 inflammasome pathway has been implicated in trained immunity and in various autoinflammatory disorders, which must be considered in the development of training-based therapeutics (<xref ref-type="bibr" rid="bib103">Lee et al., 2023a</xref>; <xref ref-type="bibr" rid="bib109">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Christ et al., 2018</xref>). For example, in a mouse model of periodontitis, an oral inflammatory disease, increased systemic inflammation led to IL-1 receptor-mediated maladaptive central training of HSCs. These mice were then more susceptible to experimental arthritis (<xref ref-type="bibr" rid="bib109">Li et al., 2022</xref>). This finding suggests that acquiring central training in one autoinflammatory condition increases the risk of developing other training-driven comorbidities.</p><p>Maladaptive training of the bone marrow can also be induced by highly processed, western diets (<xref ref-type="bibr" rid="bib35">Christ et al., 2018</xref>). Altered immune metabolism from central training is linked to metabolic syndromes and type 2 diabetes through enhanced production of inflammatory cytokines (<xref ref-type="bibr" rid="bib34">Choudhury et al., 2021</xref>). These NLRP3 inflammasome-mediated trained immunity pathways have also been observed in humans in diabetes and atherosclerosis (<xref ref-type="bibr" rid="bib48">Edgar et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Bekkering et al., 2016</xref>). In one study, bone marrow was transplanted from diabetic mice to mice with normal glycemic index; these otherwise healthy mice became prone to atherosclerosis and developed lesions with necrotic, lipid-rich cores. This phenotype mirrors the increased rates of atherosclerosis observed in diabetic humans (<xref ref-type="bibr" rid="bib33">Choudhury et al., 2004</xref>).</p><p>Beyond chronic conditions and environmental factors, central training and its consequences can also occur following acute trauma. For example, a study with experimental myocardial infarction (MI) showed induction of maladaptive training of myeloid progenitors, and the trained phenotype could be transferred by bone marrow transplantation to apolipoprotein-E deficient mice on a high-fat diet (<xref ref-type="bibr" rid="bib46">Dong et al., 2024</xref>). When compared with controls that received untrained bone marrow, the mice that received bone marrow from post-MI mice exhibited elevated levels of systemic IL-1β and TNF-ɑ and increased atherosclerotic lesions.</p><p>In each of these experimental models and patient cohorts, training drives susceptibility to secondary inflammatory conditions. These direct relationships between central training and autoinflammatory diseases give pause when considering central trained immunity as a therapeutic target. If training-based therapeutics access the bone marrow and induce central training, then there is a risk of inducing or worsening these training-mediated autoinflammatory conditions. However, strategies to directly inhibit central trained immunity may reduce hyper-inflammation in chronic diseases while preserving peripheral immune responses for local defense, providing a new therapeutic target for these common chronic diseases. In each of these diseases, maladaptive central training is implicated as a direct driver of pathology, and pathology can be reproduced by the adoptive transfer of the trained HSCs into naïve mice. Therefore, selective suppression of training in HSCs via bioengineering approaches such as nanotherapeutics, gene therapies, or epigenetic-directed inhibitors are promising strategies to suppress the progression of these autoinflammatory diseases. Such methods will be discussed further in the <italic>Cellular Engineering</italic> section.</p></sec><sec id="s1-1-2"><title>Peripheral trained immunity in immune and non-immune cells: targets for tissue-specific protection</title><p>Peripheral trained immunity is local and can be more transient compared to central trained immunity (<xref ref-type="fig" rid="fig2">Figure 2</xref>). This form of immunity is induced by direct environmental interactions with pathogens or other stimuli in tissue-resident cells, in tissues such as the skin and lungs (<xref ref-type="bibr" rid="bib140">Netea and Joosten, 2018</xref>). A study by <xref ref-type="bibr" rid="bib204">Yao et al., 2018</xref> found that the formation and maintenance of alveolar macrophages show memory features that occur independently of monocytes or bone marrow progenitors using a model of adenovirus lung infection (<xref ref-type="bibr" rid="bib204">Yao et al., 2018</xref>). Other tissue-resident macrophages, such as Kupffer cells or microglia, self-renew independently of HSCs, making them promising targets for lasting innate training (<xref ref-type="bibr" rid="bib115">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="bib73">Heng et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Gomez Perdiguero et al., 2015</xref>). In an immunosuppressive tumor microenvironment, β-glucan-mediated trained innate immune responses establish an anti-tumor microenvironment that may be sufficient to eradicate the typically immunosuppressive pancreatic tumor, further cementing the effectiveness of peripheral trained immunity in combating disease (<xref ref-type="bibr" rid="bib64">Geller et al., 2022</xref>). The same group demonstrated the role of interstitial macrophages in the host resistance of metastatic lesions in an intravenous melanoma model (<xref ref-type="bibr" rid="bib44">Ding et al., 2023</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Characteristics of central and peripheral trained immunity and target tissues for therapeutic induction of trained immunity.</title><p>(Top Right) Central training occurs in progenitor cells of the bone marrow (shown here via Bacille Calmette-Guérin, BCG training of hematopoietic stem cells, HSCs), leading to long-lived, multi-generational training in daughter cells. Central training is also directly implicated in the pathogenesis of autoinflammatory diseases, such as atherosclerosis and diabetes. Directed targeting to the bone marrow can access hematopoietic stem cells for long-lived central training. (Left and Bottom) Peripheral trained immunity can encompass tissue-resident innate immune cells and stromal cells, such as epithelial cells and fibroblasts (shown here with small molecule training in the alveoli of the lung, Kupffer cells in the liver, and Peyer’s Patches in the small intestine). Peripheral training can provide local resistance to infection, cancer, and other inflammatory insults. A combination of passive and active targeting approaches can be used to access peripheral training in the lung, gut, and liver. Respiratory delivery can be achieved with aerosols, gastrointestinal delivery can be targeted with delayed release systems, and hepatic delivery can be achieved with intravenous delivery of nanoparticles, which naturally accumulate in the liver. This figure was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/fz70yp6">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106339-fig2-v1.tif"/></fig><p>Like innate immune cells, many other cell types are also capable of peripheral training with both pathogenic consequences and therapeutic benefits. Stromal cells can exhibit epigenetic and metabolic changes in the local tissue environment, consistent with peripheral training. For example, epithelial cells express PRRs, like immune cells, and produce immunomodulators and antimicrobial compounds when exposed to pathogens (<xref ref-type="bibr" rid="bib167">Schaefer et al., 2004</xref>; <xref ref-type="bibr" rid="bib132">Naik et al., 2017</xref>). One study observed that skin epithelial stem cells exhibit features consistent with innate immune memory. Using imiquimod in a model of skin inflammation, the authors observed that the skin previously exposed to imiquimod not only reacted more quickly to an unrelated secondary challenge but also exhibited more rapid wound healing than skin of naïve mice (<xref ref-type="bibr" rid="bib132">Naik et al., 2017</xref>). This memory response has been attributed to epigenetic changes in the stem cells of the skin.</p><p>Inflammatory memory in epithelial cells is not limited to the skin—it has also been reported in the gut. Intestinal stromal cells also respond to bacterial pathogens and have been suggested to exhibit immunological memory (<xref ref-type="bibr" rid="bib145">Novakovic and Stunnenberg, 2017</xref>; <xref ref-type="bibr" rid="bib150">Owens, 2015</xref>). Intestinal stromal cells produce prolonged proinflammatory cytokines that aid in recruiting immune cells to the site of infection during a secondary challenge (<xref ref-type="bibr" rid="bib150">Owens, 2015</xref>; <xref ref-type="bibr" rid="bib148">Owens and Simmons, 2013</xref>; <xref ref-type="bibr" rid="bib149">Owens et al., 2013</xref>). Further studies reported that fibroblasts also respond to pathogens by interacting with other cells through the production of inflammatory signals (<xref ref-type="bibr" rid="bib91">Kaufman et al., 2001</xref>). Studies have revealed that fibroblasts are involved in the persistence of inflammation: when activated during infection, tissue repair triggers a protective immune response through the recruitment of immune cells to clear infections and rebuild tissue (<xref ref-type="bibr" rid="bib91">Kaufman et al., 2001</xref>; <xref ref-type="bibr" rid="bib17">Bautista-Hernández et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Flavell et al., 2008</xref>).</p><p>Together, these studies highlight the importance of tissue-specific training cues and their ability to halt the spread of infection. The variable durability, cell specificity, and tissue-specific response of peripheral training provide opportunities to use bioengineering to create tissue-specific vaccines and therapies that enhance host defenses while minimizing the risk of harmful inflammatory responses posed by central trained immunity. Approaches to selectively target peripheral trained immunity will be explored in the <italic>Passive and Active Targeting Approaches</italic>.</p></sec></sec><sec id="s1-2"><title>Therapeutic targets and challenges for trained immunity</title><p>Selectively modulating peripheral innate immune memory could provide opportunities to create therapies that strengthen host defense while minimizing harmful inflammatory responses, albeit with many challenges. For example, local tissue training can, in some cases, lead to systemic therapeutic effects. Talimogene laherparepvec (T-VEC), a modified herpes simplex virus engineered to encode GM-CSF, exerts anti-tumor effects through direct oncolysis at the site of administration but also through innate immune cell-driven systemic responses. This virus has been approved by the FDA to treat unresectable melanoma (<xref ref-type="bibr" rid="bib92">Kaufman et al., 2022</xref>; <xref ref-type="bibr" rid="bib85">Jennings et al., 2019</xref>). Another example where trained immunity has been attributed to increased systemic effects includes the anti-tumor response following intratumoral administration of mRNA encoding IL-12, IFN-ɑ, IL-15, and GM-CSF (<xref ref-type="bibr" rid="bib79">Hotz et al., 2021</xref>). Delivering mRNA encoding tumor-specific antigens or cytokines to antigen-presenting cells (APCs) can result in a systemic anti-tumor response mediated by the local innate immune activation (<xref ref-type="bibr" rid="bib161">Rojas et al., 2023</xref>; <xref ref-type="bibr" rid="bib26">Cafri et al., 2020</xref>; <xref ref-type="bibr" rid="bib166">Sahin et al., 2020</xref>). Most recently, trained immunity has been applied to sepsis treatment to overcome immune paralysis using the potential of apolipoprotein nanotechnology (<xref ref-type="bibr" rid="bib168">Schrijver et al., 2023</xref>. <xref ref-type="bibr" rid="bib168">Schrijver et al., 2023</xref>) discovered that apolipoprotein nanoparticles loaded with IL-4 could control sepsis via induction of trained immunity in myeloid cells (<xref ref-type="bibr" rid="bib168">Schrijver et al., 2023</xref>). In each of these models, the training of peripheral innate immune cells coordinated a protective systemic response.</p><p>Exploiting trained immunity mechanisms could also enhance vaccine efficacy, particularly for populations with weakened immune systems – notably the elderly, young children, and the immunocompromised. Trained memory has been attributed to the nonspecific effects of vaccines against unrelated illnesses which have been demonstrated in many pre-clinical and clinical studies (<xref ref-type="bibr" rid="bib211">Ziogas and Netea, 2022</xref>; <xref ref-type="bibr" rid="bib43">Del Fresno et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Goodridge et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Benn et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Higgins et al., 2016</xref>). Animal studies demonstrated that BCG vaccination conferred protection against candidemia in severe combined immunodeficiency disease (SCID) mice, which lack all adaptive immune cells, alluding to the protective effects of innate memory (<xref ref-type="bibr" rid="bib96">Kleinnijenhuis et al., 2012</xref>). It has also been observed that BCG-induced training conferred nonspecific protection against malaria and viral infection in humans (<xref ref-type="bibr" rid="bib12">Arts et al., 2018</xref>; <xref ref-type="bibr" rid="bib190">Walk et al., 2019</xref>). In elderly patients, non-specific BCG protection has been observed against respiratory infections (<xref ref-type="bibr" rid="bib65">Giamarellos-Bourboulis et al., 2020</xref>). Similarly, a new tuberculosis vaccine, VPM1002, also conferred non-specific protection against severe respiratory infections in the elderly (<xref ref-type="bibr" rid="bib23">Blossey et al., 2023</xref>). Another example of the broader protection offered by trained immunity is MTBVAC, a live attenuated tuberculosis vaccine that confers heterologous protection against <italic>Streptococcus pneumoniae</italic> (<xref ref-type="bibr" rid="bib180">Tarancón et al., 2020</xref>). Signatures of trained innate immunity were also observed in humans after SARS-CoV-2 infection. The Pfizer mRNA vaccine, BNT162b2, induced short-term epigenetic memory in innate immune cells (<xref ref-type="bibr" rid="bib202">Yamaguchi et al., 2022</xref>).</p><p>Vaccine adjuvants have also been demonstrated to induce trained immunity signatures. For example, the addition of oil-based adjuvant AS03 in an influenza vaccine induces epigenetic changes in myeloid cells, generating in vitro resistance to unrelated viruses such as Dengue and Zika (<xref ref-type="bibr" rid="bib199">Wimmers et al., 2021</xref>). A TLR7/8 agonist, 3M052, also drives epigenetic and transcriptomic modifications in murine myeloid cells (<xref ref-type="bibr" rid="bib102">Lee et al., 2022</xref>). Thus, trained immunity-related epigenetic changes in myeloid cells may increase the responsiveness of these trained cells to subsequent vaccine doses and improve the crosstalk between lymphocytes and myeloid cells during vaccination. In clinical applications, trained immunity can independently enhance protection against diseases and amplify the response to immune-targeted therapies, like vaccines and cancer treatments.</p></sec><sec id="s1-3"><title>Passive and active targeting approaches</title><sec id="s1-3-1"><title>Cellular delivery</title><p>While both central and peripheral training can play a role in therapeutic protection and pathogenesis, targeting these compartments directly within cells and tissues remains an unaddressed challenge. One approach to cell-specific, targeted delivery of trained immunity-inducing stimuli is nanocarriers. Nanocarriers can target many tissues, including the gut and lung, and can be directed to nearly any cell type. However, they are naturally suited to target cells of the mononuclear phagocyte system, especially macrophages, which are primary drivers of trained immunity.</p><p>Targeting specific cell types via surface markers is a common bioengineering strategy in vaccines, treatment of cancer, and other inflammatory diseases (<xref ref-type="bibr" rid="bib51">Ellipilli et al., 2023</xref>; <xref ref-type="bibr" rid="bib80">Hua et al., 2015</xref>; <xref ref-type="bibr" rid="bib170">Shi et al., 2024</xref>; <xref ref-type="bibr" rid="bib94">Kim et al., 2013</xref>). Conjugated or self-assembled delivery systems can be decorated with natural ligands, synthetic peptides, or nanobodies with target-specific binding affinity as a method of active targeting (<xref ref-type="bibr" rid="bib9">Arias et al., 2015</xref>; <xref ref-type="bibr" rid="bib209">Zhou et al., 2025</xref>; <xref ref-type="bibr" rid="bib104">Lee et al., 2023b</xref>; <xref ref-type="bibr" rid="bib183">Tian et al., 2022</xref>; <xref ref-type="bibr" rid="bib184">Tong et al., 2021</xref>). Depending on the designs of these targeting moieties and the function of their cognate receptor, the binding event can induce drug uptake, activation of signaling, or inhibition of signaling (<xref ref-type="bibr" rid="bib15">Bajracharya et al., 2022</xref>; <xref ref-type="bibr" rid="bib171">Slezak et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Duan and Luo, 2021</xref>). Encapsulation in nanocarriers may also reduce off-target effects and toxicities that limit the dosing of a drug, as in the case of the chemotherapeutic doxorubicin when formatted in liposomes as Doxil (<xref ref-type="bibr" rid="bib197">Waterhouse et al., 2001</xref>).</p><p>In addition to active targeting approaches, nanoparticle morphology can be designed to influence uptake in specific tissues or cell types via passive targeting. Inherent characteristics of nanomaterials, including surface charge, shape, size, and topography are known to affect their uptake and distribution in vivo (<xref ref-type="bibr" rid="bib127">Mitragotri and Lahann, 2009</xref>; <xref ref-type="bibr" rid="bib29">Champion and Mitragotri, 2006</xref>; <xref ref-type="bibr" rid="bib13">Augustine et al., 2020</xref>). For example, to bias delivery to phagocytic cells, such as macrophages, size- and morphology-restricted nanoparticles can be useful. Macrophages preferentially uptake particles upwards of 400 nm in size, whereas neutrophils prefer elongated, rod-shaped particles (<xref ref-type="bibr" rid="bib165">Safari et al., 2020</xref>; <xref ref-type="bibr" rid="bib108">Li et al., 2021</xref>). These nanoparticles can have many different compositions and characteristics, from complex lipid nanoparticles to self-assembling polymersomes, each with different properties and benefits (<xref ref-type="table" rid="table1">Table 1</xref>). Liposome-based systems, in particular, offer a non-inflammatory, inexpensive method for the delivery of both hydrophobic and hydrophilic cargo (<xref ref-type="bibr" rid="bib125">Minocha and Kumar, 2022</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Some nanocarrier types and characteristics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Type</th><th align="left" valign="top">Advantages</th><th align="left" valign="top">Disadvantages</th></tr></thead><tbody><tr><td align="left" valign="top">Polymeric <xref ref-type="bibr" rid="bib118">Lu et al., 2021</xref></td><td align="left" valign="top"><list list-type="bullet" id="list1"><list-item><p>Stability</p></list-item><list-item><p>More amenable to surface decoration</p></list-item><list-item><p>Controlled release</p></list-item><list-item><p>Can be designed for stimulus-specific degradation</p></list-item></list></td><td align="left" valign="top"><list list-type="bullet" id="list2"><list-item><p>No endosomal escape mechanism</p></list-item><list-item><p>Lower loading ability</p></list-item><list-item><p>Immunogenic</p></list-item><list-item><p>Difficult to synthesize in a controlled fashion</p></list-item></list></td></tr><tr><td align="left" valign="top">Liposomes, Micelles, and Emulsions <xref ref-type="bibr" rid="bib118">Lu et al., 2021</xref></td><td align="left" valign="top"><list list-type="bullet" id="list3"><list-item><p>Modular components</p></list-item><list-item><p>FDA-approved products</p></list-item><list-item><p>Biocompatible</p></list-item><list-item><p>Simple to produce</p></list-item><list-item><p>Can load hydrophobic and hydrophilic cargo</p></list-item></list></td><td align="left" valign="top"><list list-type="bullet" id="list4"><list-item><p>Scale up</p></list-item><list-item><p>Extra-hepatic delivery is challenging</p></list-item><list-item><p>Less stable</p></list-item></list></td></tr><tr><td align="left" valign="top">Lipid Nanoparticles <xref ref-type="bibr" rid="bib118">Lu et al., 2021</xref></td><td align="left" valign="top"><list list-type="bullet" id="list5"><list-item><p>FDA-approved products</p></list-item><list-item><p>Ideal for nucleic acid cargo</p></list-item><list-item><p>Endosomal escape</p></list-item><list-item><p>Biocompatible</p></list-item></list></td><td align="left" valign="top"><list list-type="bullet" id="list6"><list-item><p>Immunogenic</p></list-item><list-item><p>Extra-hepatic delivery is challenging</p></list-item><list-item><p>Less stable, especially at 4 °C</p></list-item></list></td></tr><tr><td align="left" valign="top">Lipoprotein <xref ref-type="bibr" rid="bib41">Damiano et al., 2013</xref>; <xref ref-type="bibr" rid="bib181">Thaxton et al., 2016</xref></td><td align="left" valign="top"><list list-type="bullet" id="list7"><list-item><p>Biocompatible</p></list-item><list-item><p>Biomimicry</p></list-item><list-item><p>Natural metabolic trafficking target</p></list-item></list></td><td align="left" valign="top"><list list-type="bullet" id="list8"><list-item><p>Complex - quality control and scale up is costly</p></list-item><list-item><p>Purification challenges</p></list-item></list></td></tr><tr><td align="left" valign="top">Exosomes <xref ref-type="bibr" rid="bib37">Colombo et al., 2014</xref></td><td align="left" valign="top"><list list-type="bullet" id="list9"><list-item><p>Physiologic delivery system</p></list-item><list-item><p>Low risk of immunogenicity</p></list-item><list-item><p>Longer circulation times</p></list-item></list></td><td align="left" valign="top"><list list-type="bullet" id="list10"><list-item><p>Heterogeneous loading</p></list-item><list-item><p>Labor-intensive isolation</p></list-item></list></td></tr></tbody></table></table-wrap><p>Several groups are already pursuing various nanocarrier-based delivery systems to induce trained immunity. Exosomes, either engineered ex vivo or endogenously derived, can hijack the native intracellular communication system to induce or modulate training, as demonstrated via both bacterial and stem cell sources (<xref ref-type="bibr" rid="bib117">Liu et al., 2024b</xref>; <xref ref-type="bibr" rid="bib58">Feng et al., 2020</xref>). In one study from <xref ref-type="bibr" rid="bib131">Mulder et al., 2019</xref>, muramyl dipeptide (MDP) was lipidated and loaded onto a scaffold of apolipoprotein A (ApoA), the primary component of high-density lipoprotein (HDL) (<xref ref-type="bibr" rid="bib153">Priem et al., 2020</xref>). This biomimetic nanocarrier induced trained immunity in mice and significantly improved their response to checkpoint inhibition in a B16F10 melanoma model. In an alternative approach, β-glucan was encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles, resulting in extended release of β-glucan and prolongation of the training period (<xref ref-type="bibr" rid="bib4">Ajit et al., 2022</xref>). Mice that were trained with the β-glucan PLGA nanoparticles significantly resisted engraftment of B16F10 tumors. Due to their inherent interactions with innate immune cells, particularly the cells that comprise the mononuclear phagocyte system, nanoparticles are an attractive delivery modality for inducing trained immunity in a more precise and controllable manner. While nanoparticle-based induction of trained immunity is being explored in preclinical studies, there are no ongoing clinical trials using this approach.</p></sec><sec id="s1-3-2"><title>Tissue delivery</title><p>Similar methods can be used to target delivery to specific tissues rather than individual cell types, since nanocarriers also preferentially accumulate in different organs depending on their physical and chemical characteristics (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="bibr" rid="bib195">Wang et al., 2023b</xref>; <xref ref-type="bibr" rid="bib175">Su et al., 2024</xref>). For example, intravenously administered nanoparticles naturally traffic to the liver and may be useful for inducing trained immunity to prophylactically combat septic liver injury or hepatitis (<xref ref-type="bibr" rid="bib99">Kumar et al., 2023</xref>; <xref ref-type="bibr" rid="bib116">Liu et al., 2024a</xref>; <xref ref-type="bibr" rid="bib196">Wang et al., 2024</xref>; <xref ref-type="bibr" rid="bib77">Hong et al., 2015</xref>). Intravesical delivery of BCG is currently used as a trained immunity-inducing treatment in bladder cancer; therefore, targeted delivery of other inducers of training to the kidneys and epithelial cells of the urogenital tract may offer a less invasive alternative (<xref ref-type="bibr" rid="bib6">Alexandroff et al., 1999</xref>; <xref ref-type="bibr" rid="bib25">Buffen et al., 2014</xref>). This strategy may also allow researchers to selectively induce peripheral or central trained immunity, depending on the goal of the treatment. Small molecules, in particular, can easily be formulated for topical delivery to the skin, aerosol-based delivery to the respiratory mucosa, or oral delivery to the gut with delayed release capabilities (<xref ref-type="bibr" rid="bib120">Ma et al., 2021</xref>; <xref ref-type="bibr" rid="bib187">Uhl et al., 2021</xref>; <xref ref-type="bibr" rid="bib174">Souto et al., 2022</xref>; <xref ref-type="bibr" rid="bib194">Wang et al., 2023a</xref>). Several groups have demonstrated that epithelial cells of mucosal surfaces are trained by inflammatory stimuli, which then alter the expression of key adhesion molecules on their surface (<xref ref-type="bibr" rid="bib176">Subudhi et al., 2024</xref>; <xref ref-type="bibr" rid="bib163">Russell et al., 2023</xref>; <xref ref-type="bibr" rid="bib162">Rosenblum and Naik, 2022</xref>; <xref ref-type="bibr" rid="bib133">Naik and Fuchs, 2022</xref>). This phenomenon presents an exciting opportunity to modulate susceptibility to environmental exposures, infectious or otherwise, by training mucosal surfaces directly. Nanoparticle systems may also be employed to reverse the effects of trained immunity in the case of maladaptive training. Therefore, there is much interest in employing nanoparticle-based systems for the precise delivery of trained immunity-modifying therapeutics.</p></sec></sec><sec id="s1-4"><title>Biomechanical approaches</title><sec id="s1-4-1"><title>Mechanotransduction and epigenetics</title><p>A new, exciting approach to induce training is the manipulation of mechanical signaling. Mechanotransduction is critical to the ability of immune cells to communicate with adjacent or remote cells, to migrate to the site of infection, or to adapt to disrupted local environments. These processes rely on the cell’s ability to sense both the biochemical and mechanical changes around them (<xref ref-type="bibr" rid="bib200">Wozniak et al., 2004</xref>; <xref ref-type="bibr" rid="bib63">Geiger et al., 2009</xref>). Disruptions and changes in the stresses and strains in the extracellular matrix (ECM) can stem from numerous sources, such as degraded ECM during a bacterial infection. Cells sense such mechanical changes in their microenvironment via focal adhesions, a specialized complex of adhesion proteins. In particular, integrins are a superfamily of transmembrane cell receptors that comprise focal adhesions (<xref ref-type="bibr" rid="bib78">Hood and Cheresh, 2002</xref>). Integrins are crucial mechanotransducers, converting mechanical forces from the ECM into intracellular biochemical signals and vice versa.</p><p>The activation of mechanical signaling stimulates intracellular signaling cascades that affect numerous cellular processes, such as differentiation, proliferation, tissue development, migration, or survival. The cross-linking of integrins and binding to their ligands activate downstream signaling proteins, which propagate the extracellular mechanical signals to the nucleus via the cytoskeletal network (<xref ref-type="bibr" rid="bib126">Miranti and Brugge, 2002</xref>). Various nucleoskeletal machinery, namely the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, is then involved to propagate the signal through the nuclear envelope and nuclear lamina to reach the chromatin. Mechanical signals transduced to the nucleus can alter chromatin structure and activate various transcription factors (TFs) that drive specific regulation of gene expression. Studies showed that actomyosin contraction induced by a stiffer environment led to nuclear flattening, which caused nuclear localization and accumulation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) downstream. This cascade led to the strengthening of the focal adhesion and cytoskeletal network, as YAP/TAZ controls the activation of genes encoding focal adhesion proteins (<xref ref-type="bibr" rid="bib52">Elosegui-Artola et al., 2017</xref>; <xref ref-type="bibr" rid="bib95">Kim and Gumbiner, 2015</xref>; <xref ref-type="bibr" rid="bib134">Nardone et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Aragona et al., 2013</xref>).</p><p>Our current understanding of how mechanotransduction can alter and influence the transcriptomic and epigenetic landscape is still evolving. A recent study demonstrated that local stress applied to the cell surface led to chromatin stretching that depended on the loading direction (<xref ref-type="bibr" rid="bib178">Tajik et al., 2016</xref>). Mechanical force-induced remodeling of chromatin also depends on the duration of force. Short durations of force applied to the cell surface, within seconds, initiate immediate stretching of the chromatin and upregulation of mechanosensitive genes, such as <italic>Cav1</italic> or <italic>egr-1</italic>, mediated by H3K9me3 demethylation (<xref ref-type="bibr" rid="bib177">Sun et al., 2020</xref>). In contrast, longer exposure to force, in duration of hours, leads to dynamic adaptation by the chromatin to minimize the strain on the nucleus, an unconventional method to maintain genome integrity in response to mechanical deformation (<xref ref-type="bibr" rid="bib136">Nava et al., 2020</xref>).</p><p>Interestingly, many studies note the importance of mechanical stimulation in the induction of longer-term changes in cell phenotypes by epigenetic modifications. For example, the lineage commitment of mesenchymal stem cells is reliant on mechanical cues. Mesenchymal stem cells (MSCs) seeded in stiffer substrates undergo osteogenic differentiation; in softer substrates, they undergo adipogenic or neuronal differentiation (<xref ref-type="bibr" rid="bib53">Engler et al., 2006</xref>). Rapid ATP synthesis ensuing dynamic loading enables chromatin condensation, a key step in differentiation, showing the importance of mechanical loading on both metabolic and epigenetic regulation (<xref ref-type="bibr" rid="bib74">Heo et al., 2016</xref>). Matrix stiffness can regulate nuclear translocation of both methyltransferases and acetyltransferases, inducing methylation, or chromatin condensation, and acetylation, or chromatin relaxation, respectively (<xref ref-type="bibr" rid="bib84">Jang et al., 2021</xref>; <xref ref-type="bibr" rid="bib208">Zhao et al., 2021</xref>; <xref ref-type="bibr" rid="bib173">Song et al., 2024</xref>). In summary, mechanical force is a crucial cellular signal that controls gene expression and has potential as a robust method to manipulate epigenetics.</p></sec><sec id="s1-4-2"><title>Scaffold-based manipulation of epigenetics</title><p>The forces applied onto cells by scaffolds or extracellular matrices provide stress-strain stimulation to cells often necessary for homeostasis. Consequently, changes in the scaffold can lead to altered cellular responses. For example, the high-tension environment made by the highly aligned and packed collagen fibers in tendons promotes an anabolic state in tenocytes at homeostasis. The loss of this tension leads to a decrease in chromatin accessibility in tenocytes, increasing the expression of a matrix of catabolic genes (<xref ref-type="bibr" rid="bib88">Jones et al., 2023</xref>). In bone, sensitivity to fluid shear stress has been shown to be enhanced by Sirtuin-3, a histone deacetylase, which also plays an important role in regulating bone mass (<xref ref-type="bibr" rid="bib110">Li et al., 2023a</xref>). In another study with chondrocytes, three-dimensional hydrogels were used to demonstrate the importance of mechanical memory on chondrogenic potential by comparing the threshold after exposure to a two-dimensional stiff substrate (<xref ref-type="bibr" rid="bib169">Scott et al., 2023</xref>). Importantly, a recent study reported on the pivotal role of integrin-mediated adhesion in regulating the epigenetic landscape to restrict DC maturation (<xref ref-type="bibr" rid="bib69">Guenther et al., 2021</xref>). Additionally, adhesion-mediated reprogramming led to less effective anti-tumor responses by DCs, further suggesting the critical role of mechanical cues in maintaining immune cell phenotype and function (<xref ref-type="bibr" rid="bib71">Harjunpää et al., 2024</xref>).</p><p>Engineered scaffolds create the opportunity to control mechanosensing and exposure to biochemical signals via encapsulation to induce cellular processes such as neurogenic, chondrogenic, or osteogenic differentiation (<xref ref-type="bibr" rid="bib172">Soltani et al., 2024</xref>; <xref ref-type="bibr" rid="bib151">Peng, 2024</xref>; <xref ref-type="bibr" rid="bib205">Zahedi Tehrani et al., 2024</xref>). In a study using chitosan hydrogel encapsulating chemotactic simvastatin and osteogenic pargyline, endogenous stem cells were successfully recruited to promote osteogenic differentiation and bone regeneration (<xref ref-type="bibr" rid="bib191">Wan et al., 2022</xref>). This scaffold promoted in situ bone regeneration by inducing epigenetic changes akin to training in the MSCs.</p><p>Bioengineered scaffolds can help answer many important questions related to trained immunity, including the epigenetic effects of relative stress, forces over a defined period of time, and the mechanics at interfaces and in three dimensions. Various platforms have been developed to study mechanotransduction, from simple coated cell culture plates to elaborate scaffolds (<xref ref-type="fig" rid="fig3">Figure 3</xref>). For example, collagen can be coated onto cell culture plates to study two-dimensional cell stretching, but also be used to fabricate three-dimensional gels to create in vivo-like matrices (<xref ref-type="bibr" rid="bib70">Hackett et al., 2022</xref>). Specific tissues of interest can be modeled by using different polymers or manufacturing techniques. Crosslinking of chitosan and gelatin, followed by lyophilization yields highly porous scaffolds that can be seeded with MSCs to mimic bone tissue (<xref ref-type="bibr" rid="bib27">Carvalho et al., 2024</xref>). Electrospinning of nanofibers can create ECM-like scaffolds and has high flexibility to incorporate other bioactive molecules. In a study using coaxial electrospinning, scaffolds were made of polycaprolactone and gelatin with zinc oxide and silicon dioxide nanoparticles to form a biomimetic periosteum. These scaffolds demonstrated high osteogenic differentiation ability and promoted an M2 phenotype of macrophages when seeded into the scaffolds (<xref ref-type="bibr" rid="bib210">Zhuang et al., 2025</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Types of biomechanical modulation achieved with native and engineered in vitro, ex vivo, and in vivo systems.</title><p>Engineered scaffolds can model fluid flow, porous environments, fibrosis, and healthy extracellular matrices. Shear stress from turbulent fluid flow impacts endothelial cell susceptibility to atherosclerosis, likely due to trained immunity. Porous scaffolds can provide niches for cellular interaction, differentiation, and drug encapsulation. Fibrotic and native extracellular matrix (ECM), which exhibit differences in elasticity, stiffness, and ligand expression, can be used to measure the effects of mechanotransduction on training in healthy and diseased tissues. This figure was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/x5h6mk1">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106339-fig3-v1.tif"/></fig><p>Scaffolds can be engineered to have specific mechanical properties and can be put under different types of stress in vitro (<xref ref-type="bibr" rid="bib142">Ni et al., 2023</xref>; <xref ref-type="bibr" rid="bib201">Xu et al., 2022</xref>; <xref ref-type="bibr" rid="bib198">Whitehead et al., 2018</xref>; <xref ref-type="bibr" rid="bib158">Ramey-Ward et al., 2023</xref>). Specifically, cells can be put under shear stress from fluid flow. For cells like endothelial cells, shear stress-induced mechanotransduction is critical to some key molecules such as eNOS, an important target for prevention of atherosclerosis (<xref ref-type="bibr" rid="bib72">Hecker et al., 1994</xref>). Cell culture can be set up under laminar flow, unidirectional flow to mimic healthy conditions, or disturbed flow to mimic hemodynamics prone to atherogenesis (<xref ref-type="bibr" rid="bib112">Li et al., 2024</xref>).</p><p>Overall, these studies show scaffolds can induce epigenetic changes by providing mechanical cues and by acting as deposits of molecules that induce epigenetic reprogramming. Additionally, bioengineered scaffolds are inexpensive, easily modifiable tools to interrogate the role of mechanosensing in trained immunity. How these mechanical cues influence trained immunity in cells, both independently and in the context of chemical signals, remains a clear gap in knowledge that could be addressed with bioengineering approaches.</p></sec></sec><sec id="s1-5"><title>Cellular engineering</title><p>Epigenetic and metabolic reprogramming are the principal mechanisms underlying the induction and maintenance of trained immunity. Epigenetic modification of histones, especially H3K4Me1, H3K4Me3, and H3K27Ac, increases the accessibility of chromatin in trained innate immune cells, thus improving their ability to rapidly transcribe effector proteins on demand (<xref ref-type="bibr" rid="bib144">Novakovic et al., 2016</xref>; <xref ref-type="bibr" rid="bib164">Saeed et al., 2014</xref>). This process is influenced by a set of long non-coding RNAs (lncRNAs) called immune gene priming lncRNAs (IPLs), which alter the 3D structure of the genome to facilitate epigenetic training (<xref ref-type="bibr" rid="bib54">Fanucchi et al., 2019</xref>). Furthermore, transcription factors (TFs), including Jun and Fos, play a role in both the establishment and maintenance of training-induced epigenetic modifications (<xref ref-type="bibr" rid="bib100">Larsen et al., 2021</xref>). Though it is a defining feature, epigenetic reprogramming is not the only hallmark of trained immunity. Alterations in cellular metabolism are necessary for the induction of training in a variety of model systems. Trained innate immune cells are more metabolically active than their untrained counterparts. The first known metabolic pathway demonstrated to be upregulated in trained immunity was glycolysis (<xref ref-type="bibr" rid="bib31">Cheng et al., 2014</xref>). Blocking glycolysis using a non-hydrolyzable form of glucose inhibits training by BCG or β-glucan (<xref ref-type="bibr" rid="bib31">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Arts et al., 2016a</xref>). Exploiting native cellular metabolism by modulating intermediate metabolites directly can also result in a trained phenotype in human monocytes, as in the case of mevalonate and itaconate (<xref ref-type="bibr" rid="bib19">Bekkering et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Domínguez-Andrés et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Ferreira et al., 2023</xref>). This upregulation in glycolysis results in the accumulation of metabolic intermediates that are used as methyl- and acetyl-group sources for histone-modifying enzymes; therefore, the epigenetic and metabolic drivers of trained immunity are inherently linked (<xref ref-type="bibr" rid="bib11">Arts et al., 2016b</xref>; <xref ref-type="bibr" rid="bib55">Fanucchi et al., 2021</xref>; <xref ref-type="bibr" rid="bib160">Riksen and Netea, 2021</xref>).</p><p>The mechanisms underlying trained immunity are complex and intertwined, making it difficult to separate the contributions of individual pathways. Moreover, recent studies suggest changes in chromatin and RNA profiles in the context of trained immunity are stimulus-specific (<xref ref-type="bibr" rid="bib97">Knight et al., 2024</xref>; <xref ref-type="bibr" rid="bib147">O’Farrell et al., 2025</xref>). While these exciting discoveries suggest current therapies could be improved with disease-specific immune training programs, deeper mechanistic insight into stimulus-specific training pathways is needed. To deconstruct and interrogate the individual genetic pathways involved in trained immunity, high-throughput screening is an efficient and effective method. Two types of screens are frequently used to identify genetic programs contributing to trained phenotypes due to their efficiency and flexibility: small-molecule screens and single-guide RNA (sgRNA) CRISPR screens (<xref ref-type="bibr" rid="bib38">Covarrubias et al., 2020</xref>). Small-molecule functional assays may be used to identify molecular pathways of interest and potential drugs simultaneously, but target identification remains an outstanding issue with this technique. Alternatively, sgRNA CRISPR knockout screening enables the identification of a specific target gene, but does not offer a potential therapeutic. Both small-molecule and CRISPR screens have identified genes involved in macrophage inflammatory pathways. As we begin to understand which genes, histone modifications, and metabolic pathways are required for training through screening techniques, deep sequencing, and metabolomics, novel clinical treatments for patients can be developed (<xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="bibr" rid="bib87">John et al., 2022</xref>; <xref ref-type="bibr" rid="bib206">Zhang et al., 2022</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Methods and targets for cellular engineering of trained immunity.</title><p>(<bold>A</bold>) As we use screening tools to elucidate the role of trained innate cells in additional autoimmune and inflammatory disorders, this concept will have increasingly more applications when designing therapeutics, including the activation and suppression of training programs. (<bold>B</bold>) Trained chimeric antigen receptor (CAR):-Macs generated ex vivo could resist immunosuppression of the tumor microenvironment to promote tumor cell death. (<bold>C</bold>) For example, trained immunity in atherosclerosis has been shown to contribute to disease pathogenesis and appears to be NLRP3 dependent (<xref ref-type="bibr" rid="bib139">Netea et al., 2016</xref>; <xref ref-type="bibr" rid="bib129">Moorlag et al., 2020</xref>). <italic>Knocking down NLRP3 expression in patient macrophages could decrease disease burden</italic>. This figure was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/d0d8z5p">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106339-fig4-v1.tif"/></fig><p>Gene-editing technologies have improved drastically in the past decades, enabling targeted gene editing with few off-target effects in patients for the first time with CRISPR-Cas9 and lentiviral vectors (<xref ref-type="bibr" rid="bib57">FDA News Release, 2023</xref>; <xref ref-type="bibr" rid="bib61">Frangoul et al., 2024</xref>; <xref ref-type="bibr" rid="bib56">FDA, 2022</xref>; <xref ref-type="bibr" rid="bib114">Libmeldy, 2020</xref>). CRISPR-Cas9 systems use an RNA guide to position the Cas9 enzyme at the complementary gene on the DNA. The enzyme then cuts the DNA and the sequence of interest is either removed or replaced with a mutation or insertion, leading to a knockdown, or a gene replacement, respectively (<xref ref-type="bibr" rid="bib111">Li et al., 2023b</xref>). A recent study by <xref ref-type="bibr" rid="bib186">Tremblay et al., 2025</xref> successfully used Cas9 epigenetic editing to reduce cholesterol levels in mice (<xref ref-type="bibr" rid="bib186">Tremblay et al., 2025</xref>). Future applications may allow deposition or removal of specific training markers onto the DNA to modulate a training response. For example, it may be possible to suppress the glycolytic amplification of trained immunity by modulating the expression of key intermediate enzymes. By reducing the availability of metabolic intermediates, there could be a decrease in epigenetic modifications and therefore training in the affected cells.</p><p>A current challenge of this approach is the delivery process; CRISPR-Cas systems must be delivered to cells via viral vector, nanoparticles, electroporation, or another method prior to the introduction of sgRNA targeting the gene of interest. Alternatively, lentiviral vectors, or retroviruses engineered to prevent viral replication, can be used to deliver desired genetic materials to a cell directly, without the need for a Cas system. Lentiviral systems simplify delivery by encoding the gene of interest directly into the delivery agent. However, lentiviruses have fewer applications than CRISPR-Cas9, as control over their integration site is limited. Although specific retroviruses have preferences for certain insertion sites in the genome, variations in insertion location exist, increasing the likelihood of off-target effects and preventing directed gene knockdowns (<xref ref-type="bibr" rid="bib152">Poletti and Mavilio, 2021</xref>).</p><p>Another approach to improve the delivery of genetic components to a specific cellular subset is autologous cell therapy (ACT). This approach involves removing the cell population of interest from a patient, manipulating the cells to have certain characteristics or gene-expression patterns, and infusing them back into the patient (<xref ref-type="bibr" rid="bib50">El-Kadiry et al., 2021</xref>). By using gene-editing technologies in combination with ACT, key genes can be over- or under-expressed in harvested cells to return them to a state of healthy activity, ideally abating the disease phenotypes upon reinfusion. For instance, patients with immunodeficiencies may benefit from increased immune system activation via the overexpression of a core training gene in macrophages. Once a gene to induce the desired training phenotype is identified, this gene could be overexpressed in patient macrophages ex vivo with CRISPR-Cas9, and the trained cells could be reinfused into the patient, resulting in a decreased occurrence of infections.</p><p>Chimeric antigen receptor (CAR) macrophages are a newer ACT, analogous to CAR T cells. Immunocompromised patients may benefit from receiving such an ACT in which macrophages are produced with a trained phenotype before being infused back into the patient. CAR macrophages (also known as CAR-Macs) are currently in clinical trials for cancer treatment due to their ability to infiltrate the tumor microenvironment as tumor-associated macrophages (TAMs) (<xref ref-type="bibr" rid="bib159">Reiss et al., 2025</xref>). Macrophages are processed ex vivo to express a tumor-specific receptor, becoming CAR-Macs that preferentially accumulate in the tumor. Training CAR-Macs before infusion could allow them to resist the immunosuppressive signals of the tumor microenvironment. By overexpressing key genes involved in training to increase immunogenicity, the tumor environment could be flipped from ‘cold’ and immunosuppressive to ‘hot’ and immunocompetent, thus improving patient outcomes. In summary, cellular engineering can deepen our fundamental understanding of trained immunity by identifying the core genes underlying the training mechanism and expand therapeutic applications of innate training by direct cellular manipulation.</p></sec><sec id="s1-6"><title>Computational systems and machine learning</title><p>During the past several years, machine learning tools and their applications have revolutionized drug discovery and mechanistic research. Trained immunity, with its history rooted in large, complex datasets, is uniquely poised to benefit from these approaches. Particularly, bioinformatics and machine learning systems can be used to identify evidence of training in epidemiologic and clinical datasets, integrate training signals across omics platforms, and identify novel pathways and targets for investigation.</p><p>Trained immunity was first described after infants vaccinated with Bacille Calmette-Guerin (BCG) displayed non-specific disease resistance, resulting in reduced infant mortality (<xref ref-type="bibr" rid="bib1">Aaby et al., 2011</xref>). The identification of additional trained immunity inducers from the existing pool of vaccines is limited by current vaccine approval guidelines, which do not require routine assessment of non-specific vaccine effects. <xref ref-type="bibr" rid="bib21">Benn et al., 2023</xref> proposed a novel regulatory framework for vaccine approval and regulation, which requires a holistic review of overall mortality and morbidity for all infectious diseases throughout a phase III trial (<xref ref-type="bibr" rid="bib21">Benn et al., 2023</xref>). Reliable reporting of non-specific vaccine effects (e.g. unrelated infections, inflammatory conditions, and all-cause mortality) would enable the establishment of a large epidemiological data pool with which a data-driven machine learning (ML) model can be trained to detect statistical patterns related to infection and inflammatory disease risk independent of vaccine-specific immunity. The development of such a deep learning architecture, such as this would produce an additional avenue to identify trained immunity inducers, like BCG, and further characterize training-related heterologous effects in patient populations (<xref ref-type="fig" rid="fig5">Figure 5</xref>). An analogous deep-learning model trained to extract complex patterns and correlations from high-dimensional data encompassing trained immunity-related changes in chromatin accessibility, cellular metabolism, and inflammatory cytokine production from existing immunological data sets could also pinpoint current vaccines, biologics, and other pharmaceutical agents that are likely to induce innate immune training (<xref ref-type="bibr" rid="bib179">Tang et al., 2023</xref>; <xref ref-type="bibr" rid="bib24">Bravi, 2024</xref>; <xref ref-type="bibr" rid="bib146">Ochando et al., 2023</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Pre-existing data sources for machine learning-based discovery in trained immunity.</title><p>Sequencing datasets, including transcriptomics, epigenomics, and translatomics can be integrated to determine the effects of intracellular regulation on trained immunity effector responses. A comparison of chemical and protein libraries with known training pathways can identify protein targets, pathways, and potential mechanisms for novel induction of trained immunity. Epidemiological and clinical datasets could yield particularly rich information, including the influence of genetic variants, microbiota, drugs, and disease states on trained immunity. This figure was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/g9nkmwd">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106339-fig5-v1.tif"/></fig><p>Utilizing machine learning to identify or predict the occurrence of trained immunity has become increasingly feasible due to ongoing efforts to elucidate the underlying molecular and cellular mechanisms of trained immunity. Training-induced alterations in the accessibility of chromatin regions linked to glycolysis and mRNA processing are well characterized (<xref ref-type="bibr" rid="bib31">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Arts et al., 2016a</xref>). Bock and colleagues (2024) exploited chromatin accessibility patterns present in their multi-omics data to train a ML model capable of predicting whether an individual would respond to BCG as a training stimulus based on their baseline chromatin accessibility profile (<xref ref-type="bibr" rid="bib130">Moorlag et al., 2024</xref>). Therefore, accessing the individual efficacy of any future trained immunity-based therapeutics is feasible. This advancement could be achieved by developing a deep learning ML model that is trained to predict which stimulus-specific physiological changes would display the highest efficacy in a specific population (<xref ref-type="bibr" rid="bib147">O’Farrell et al., 2025</xref>). In addition to predicting therapeutic efficacy, ML-guided genomics expression and variant analysis can be used to identify novel protein targets via pathway enrichment analysis. Incorporating known protein targets and their associated genomic regulation can also aid in elucidating novel molecular connections within relevant biological networks (<xref ref-type="bibr" rid="bib123">Mallick et al., 2023</xref>). Predicted protein targets can be further validated by evaluating their involvement in known training-associated physiological processes such as chromatin organization, long non-coding RNA transcription, DNA methylation, and cellular metabolism (<xref ref-type="bibr" rid="bib141">Netea et al., 2020</xref>).</p><p>The introduction of training-based therapies into clinical practice can be accelerated by employing in silico techniques in tandem with ML models to drive therapeutic discovery. Understanding the intricacies of protein structure, protein-protein interactions, and protein-ligand interactions has been made possible with ML tools such as AlphaFold3 and RoseTTA Fold (<xref ref-type="bibr" rid="bib14">Baek et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Abramson et al., 2024</xref>). The advancement of such in silico methods expedites drug discovery by providing increasingly accurate predictions which minimize the experimental effort required to identify and develop drug candidates. For example, these advancements allowed for the de novo protein design of small protein binders to an important innate immune cell activator, TLR3 (<xref ref-type="bibr" rid="bib3">Adams et al., 2025</xref>). Deep learning-based large language models such as PrefixProt and ProGen could be utilized to design a specialized protein-based therapy, such as a constitutively active metabolic enzyme that produces metabolic intermediates, like mevalonate or itaconate, which are known to induce training (<xref ref-type="bibr" rid="bib122">Madani et al., 2023</xref>; <xref ref-type="bibr" rid="bib68">Guan et al., 2025</xref>; <xref ref-type="bibr" rid="bib119">Luo et al., 2024</xref>).</p><p>The determination of druggable protein targets for trained immunity induction can be expedited by utilizing known small-molecule inducers for mechanistic interrogation (<xref ref-type="bibr" rid="bib97">Knight et al., 2024</xref>; <xref ref-type="bibr" rid="bib5">Ajit et al., 2024</xref>). Unlike endogenous signalling molecules and pathogen-derived sources, such as BCG and β-glucan, which have been used for mechanistic interrogation thus far, the use of small molecules is well precedented in in silico ligand-based target prediction tools such as SwissTargetPrediction and TargetHunter (<xref ref-type="bibr" rid="bib192">Wang et al., 2013</xref>; <xref ref-type="bibr" rid="bib203">Yang et al., 2023</xref>; <xref ref-type="bibr" rid="bib107">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Daina et al., 2019</xref>). In addition to providing additional in silico and experimental methods for druggable target prediction, small molecule-based mechanistic interrogation creates an avenue for which peripheral or central trained immunity-specific targets can be recognized by an artificial neural network (ANN)-based machine learning architecture (<xref ref-type="bibr" rid="bib113">Liao et al., 2022</xref>). Additional small molecule training inducers could be identified with data-driven ML models, which systematically guide high-throughput molecular screening via quantitative structure-activity relationship (QSAR) study (<xref ref-type="bibr" rid="bib22">Bernatavicius et al., 2024</xref>; <xref ref-type="bibr" rid="bib143">Niazi and Mariam, 2023</xref>). With limited small-molecule screening data, a deep representational learning-based QSAR framework can identify candidate molecules by iterative feedback from additional experimental data and molecular docking simulations (<xref ref-type="bibr" rid="bib179">Tang et al., 2023</xref>). While it is still unclear where trained immunity and machine learning will intersect, the many opportunities created by these computational models offer exciting new areas of research in immunology and engineering.</p></sec><sec id="s1-7"><title>Conclusions and future directions</title><p>As our understanding of the applications of trained immunity continues to grow, new approaches are needed to fully explore the therapeutic and fundamental aspects of training, which are inextricably connected. While the implications of trained immunity in the context of autoinflammatory and autoimmune disease are rapidly expanding, practical approaches to suppress maladaptive training and engage the beneficial applications of training in human diseases are still lacking.</p><sec id="s1-7-1"><title>Looking towards the future: the clinical state of trained immunity therapeutics</title><p>While there are clear clinical implications for applying trained immunity to the treatment of disease, most new human studies on trained immunity are early-stage observational studies with descriptive in vitro endpoints rather than interventional clinical trials. For example, current clinical studies on trained immunity in the recruitment phase include: vaccination with live vaccines including BCG, MMR (<xref ref-type="bibr" rid="bib49">Eklöf, 2024</xref>), and yellow fever (<xref ref-type="bibr" rid="bib83">Institut Pasteur, 2024</xref>), and inactivated tuberculosis vaccine MV130 <xref ref-type="bibr" rid="bib82">Inmunotek, 2024</xref>; impact of sleep disorders on trained immunity in the context of COVID-19 <xref ref-type="bibr" rid="bib62">Freixinet, 2024</xref>; impact of pheochromocytoma (<xref ref-type="bibr" rid="bib157">Radboud University Medical Center, 2024</xref>), colon carcinoma, and thyroid carcinoma (<xref ref-type="bibr" rid="bib156">Radboud University Medical Center, 2023</xref>) on trained immunity with or without ex vivo exposure to additional training stimuli; and effect of statin treatment on training state in patients with high cholesterol (<xref ref-type="bibr" rid="bib32">Cheng, 2023</xref>). These studies often interrogate differences in the immune response of peripheral mononuclear cells of different patient populations, with or without certain conditions or treatments, to determine which population exhibits enhanced innate responses, without evaluating functional changes in disease processes. While these studies provide useful data and are minimally invasive to the study participants, this strategy is a major limitation of current clinical applications of trained immunity, as it is difficult to make strong claims about clinical efficacy of trained immunity from observational studies alone. Additionally, methods to suppress or reverse maladaptive central trained immunity in chronic inflammatory disease are currently understudied in clinical settings, which is unsurprising as the link between training and comorbid autoinflammatory conditions was only made in the last decade. Furthermore, with the new understanding that training responses are stimulus-specific, stimuli beyond BCG and β-glucan will be required to access other forms of trained immunity for specific applications. Future studies involving direct intervention for the modulation and prevention of disease are needed to provide clinical evidence for training-based therapies.</p></sec><sec id="s1-7-2"><title>Bioengineered therapies and the potential for combinatorial training regimens</title><p>Bioengineering-based therapies, however, are a major focus of ongoing interventional clinical trials across multiple disease areas, including cancer, tissue grafting, and chronic disease. Currently, recruiting trials using bioengineering approaches include: tissue engineering for arthritis (<xref ref-type="bibr" rid="bib188">University Hospital, Basel, Switzerland, 2025</xref>), skin grafts (<xref ref-type="bibr" rid="bib121">Ma, 2025</xref>; <xref ref-type="bibr" rid="bib86">Jiayuan, 2020</xref>; <xref ref-type="bibr" rid="bib7">Andalusian Network for Design and Translation of Advanced Therapies, 2023</xref>), and breast reconstruction <xref ref-type="bibr" rid="bib155">Quanta Medical, 2025</xref>; engineered T-cells for chronic kidney disease (<xref ref-type="bibr" rid="bib28">Centre Hospitalier Régional d’Orléans, 2024</xref>) and advanced solid tumors <xref ref-type="bibr" rid="bib182">Therapeutics, 2024</xref>; and allograft for periodontal regeneration (<xref ref-type="bibr" rid="bib154">Pulido, 2024</xref>), among many others. Each of these cases represents unique opportunities for integrating trained immunity into cutting-edge therapeutic applications. Autologous or allograft-engineered tissue may benefit from the training of epithelial cells and progenitors to enhance tissue healing and prevent graft rejection. Trained, engineered macrophages could be co-administered with engineered T-cells to enhance engraftment and efficacy in cancer or chronic kidney disease. Finally, periodontal disease has known effects on trained immunity, so integrating training suppressors alongside an allograft could mitigate the risk of concurrent autoinflammatory disease. In these systems, trained immunity may serve as adjuvant therapy to enhance the efficacy of bioengineered therapeutics.</p><p>By implementing trained immunity alongside well-tested bioengineering interventions in combinatorial approaches, trained immunity is more likely to exhibit clinically significant success. For many diseases of interest, especially cancer, engaging the innate immune system alone via trained immunity may be limited in its potential to control disease, making a combinatorial approach that also activates adaptive immunity or limits disease pathogenesis more preferable. The combinatorial approach is already in use for one training-based therapy: intravesicular BCG is commonly used as adjuvant therapy following surgical resection for the treatment of bladder cancer (<xref ref-type="bibr" rid="bib6">Alexandroff et al., 1999</xref>; <xref ref-type="bibr" rid="bib25">Buffen et al., 2014</xref>). Additionally, combinatorial therapeutic approaches are often the preferred clinical approach when evaluating experimental treatments in cancer, to mitigate both ethical and efficacy concerns.</p></sec><sec id="s1-7-3"><title>Conclusions</title><p>In this review, we propose that the strategic application of bioengineering-derived techniques would allow us to refine the activation of trained immunity for safer, more localized, and more effective training-based therapeutics. For localization, nanotherapeutics are modular, well-studied systems that can precisely deliver inducers of trained immunity to select tissues. For effectiveness, understanding the biomechanics of training at a cellular level will influence our approach to studying and manipulating trained cells in both in vivo and ex vivo experimental systems and therapeutics. For clinical translation, using training in cell-based therapies is a key next step to ensure these highly effective, costly therapeutics retain their function in suppressive disease microenvironments. Conversely, using cellular engineering to turn off training in hyperinflammatory states could slow the progression of diseases like atherosclerosis. Looking toward the near future, machine learning can identify trained immunity phenotypes in pre-existing, multi-omic, and clinical datasets. Employing ML models to determine where training already occurs will improve our understanding of the landscape of training, both in detrimental and protective cases. Bioengineering will be both necessary and sufficient to transition trained immunity from scientific observation to interventional therapeutics.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s2"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>H.R.K. and A.E.-K. are inventors on a patent disclosing small molecule inducers of trained immunity for the University of Chicago. All other authors declare no competing interests</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><ack id="ack"><title>Acknowledgements</title><p>This work is supported by NIAID 75N93019C00041 to AE-K. HRK is funded by the NSF Graduate Research Fellowship Program: award NSF 2140001. HT is funded by the MSTP: award NIH T32GM150375. Figures were produced in BioRender.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><name><surname>Napirna</surname><given-names>BM</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Lisse</surname><given-names>IM</given-names></name><name><surname>Stensballe</surname><given-names>L</given-names></name><name><surname>Diness</surname><given-names>BR</given-names></name><name><surname>Lausch</surname><given-names>KR</given-names></name><name><surname>Lund</surname><given-names>N</given-names></name><name><surname>Biering-Sørensen</surname><given-names>S</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?</article-title><source>The Journal of Infectious Diseases</source><volume>204</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir240</pub-id><pub-id pub-id-type="pmid">21673035</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Dunger</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Willmore</surname><given-names>L</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Bambrick</surname><given-names>J</given-names></name><name><surname>Bodenstein</surname><given-names>SW</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Hung</surname><given-names>C-C</given-names></name><name><surname>O’Neill</surname><given-names>M</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Žemgulytė</surname><given-names>A</given-names></name><name><surname>Arvaniti</surname><given-names>E</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name><name><surname>Bertolli</surname><given-names>O</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Cherepanov</surname><given-names>A</given-names></name><name><surname>Congreve</surname><given-names>M</given-names></name><name><surname>Cowen-Rivers</surname><given-names>AI</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>FB</given-names></name><name><surname>Gladman</surname><given-names>H</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>YA</given-names></name><name><surname>Low</surname><given-names>CMR</given-names></name><name><surname>Perlin</surname><given-names>K</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Savy</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Stecula</surname><given-names>A</given-names></name><name><surname>Thillaisundaram</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>C</given-names></name><name><surname>Yakneen</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>ED</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Bapst</surname><given-names>V</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Jaderberg</surname><given-names>M</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Jumper</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title><source>Nature</source><volume>630</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07487-w</pub-id><pub-id pub-id-type="pmid">38718835</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Burtner</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>DS</given-names></name><name><surname>Dobbins</surname><given-names>C</given-names></name><name><surname>Criswell</surname><given-names>C</given-names></name><name><surname>Coventry</surname><given-names>B</given-names></name><name><surname>Tran-Pearson</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>King</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>De novo design of protein minibinder agonists of TLR3</article-title><source>Nature Communications</source><volume>16</volume><elocation-id>1234</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-025-56369-w</pub-id><pub-id pub-id-type="pmid">39890776</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajit</surname><given-names>J</given-names></name><name><surname>Cassaidy</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Solanki</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Esser Kahn</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Temporal control of trained immunity via encapsulated release of β-Glucan improves therapeutic applications</article-title><source>Advanced Healthcare Materials</source><volume>11</volume><elocation-id>e2200819</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202200819</pub-id><pub-id pub-id-type="pmid">35851855</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ajit</surname><given-names>J</given-names></name><name><surname>Knight</surname><given-names>HR</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Solanki</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Kahn</surname><given-names>APE</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Novel Non-Immunogenic Trained Immunity Inducing Small Molecule with Improved Anti-Tumor Propertie</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.03.22.585780</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandroff</surname><given-names>AB</given-names></name><name><surname>Jackson</surname><given-names>AM</given-names></name><name><surname>O’Donnell</surname><given-names>MA</given-names></name><name><surname>James</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>BCG immunotherapy of bladder cancer: 20 years on</article-title><source>Lancet</source><volume>353</volume><fpage>1689</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07422-4</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Andalusian Network for Design and Translation of Advanced Therapies</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Phase II Clinical Trial Evaluating the Safety and Efficacy of a Tissue Engineered Autologous Skin Substitute Reconstructive Surgery for Basal Cell Carcinoma</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05234658">https://clinicaltrials.gov/study/NCT05234658</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aragona</surname><given-names>M</given-names></name><name><surname>Panciera</surname><given-names>T</given-names></name><name><surname>Manfrin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors</article-title><source>Cell</source><volume>154</volume><fpage>1047</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.042</pub-id><pub-id pub-id-type="pmid">23954413</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname><given-names>JL</given-names></name><name><surname>Unciti-Broceta</surname><given-names>JD</given-names></name><name><surname>Maceira</surname><given-names>J</given-names></name><name><surname>del Castillo</surname><given-names>T</given-names></name><name><surname>Hernández-Quero</surname><given-names>J</given-names></name><name><surname>Magez</surname><given-names>S</given-names></name><name><surname>Soriano</surname><given-names>M</given-names></name><name><surname>García-Salcedo</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis</article-title><source>Journal of Controlled Release</source><volume>197</volume><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.11.002</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>La Rocca</surname><given-names>C</given-names></name><name><surname>Palma</surname><given-names>C</given-names></name><name><surname>Rodrigues</surname><given-names>F</given-names></name><name><surname>Silvestre</surname><given-names>R</given-names></name><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Lachmandas</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>LG</given-names></name><name><surname>Belinha</surname><given-names>A</given-names></name><name><surname>Cunha</surname><given-names>C</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Immunometabolic pathways in BCG-induced trained immunity</article-title><source>Cell Reports</source><volume>17</volume><fpage>2562</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.011</pub-id><pub-id pub-id-type="pmid">27926861</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Lachmandas</surname><given-names>E</given-names></name><name><surname>Rodrigues</surname><given-names>F</given-names></name><name><surname>Silvestre</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Wang</surname><given-names>S-Y</given-names></name><name><surname>Habibi</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>LG</given-names></name><name><surname>Mesquita</surname><given-names>I</given-names></name><name><surname>Cunha</surname><given-names>C</given-names></name><name><surname>van Laarhoven</surname><given-names>A</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Clish</surname><given-names>C</given-names></name><name><surname>Notebaart</surname><given-names>RA</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>807</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.10.008</pub-id><pub-id pub-id-type="pmid">27866838</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S-Y</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Reusken</surname><given-names>CBEM</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>Koopmans</surname><given-names>MP</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG Vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity</article-title><source>Cell Host &amp; Microbe</source><volume>23</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.12.010</pub-id><pub-id pub-id-type="pmid">29324233</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustine</surname><given-names>R</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>Primavera</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>RJ</given-names></name><name><surname>Thakor</surname><given-names>AS</given-names></name><name><surname>Kevadiya</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components</article-title><source>Materials Today Communications</source><volume>25</volume><elocation-id>101692</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtcomm.2020.101692</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>M</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Anishchenko</surname><given-names>I</given-names></name><name><surname>Dauparas</surname><given-names>J</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>GR</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cong</surname><given-names>Q</given-names></name><name><surname>Kinch</surname><given-names>LN</given-names></name><name><surname>Schaeffer</surname><given-names>RD</given-names></name><name><surname>Millán</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>DeGiovanni</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>JH</given-names></name><name><surname>Rodrigues</surname><given-names>AV</given-names></name><name><surname>van Dijk</surname><given-names>AA</given-names></name><name><surname>Ebrecht</surname><given-names>AC</given-names></name><name><surname>Opperman</surname><given-names>DJ</given-names></name><name><surname>Sagmeister</surname><given-names>T</given-names></name><name><surname>Buhlheller</surname><given-names>C</given-names></name><name><surname>Pavkov-Keller</surname><given-names>T</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Accurate prediction of protein structures and interactions using a three-track neural network</article-title><source>Science</source><volume>373</volume><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1126/science.abj8754</pub-id><pub-id pub-id-type="pmid">34282049</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajracharya</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>JG</given-names></name><name><surname>Patil</surname><given-names>BR</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Noh</surname><given-names>H-M</given-names></name><name><surname>Kim</surname><given-names>D-H</given-names></name><name><surname>Kim</surname><given-names>G-L</given-names></name><name><surname>Seo</surname><given-names>S-H</given-names></name><name><surname>Park</surname><given-names>J-W</given-names></name><name><surname>Jeong</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Han</surname><given-names>H-K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems</article-title><source>Drug Delivery</source><volume>29</volume><fpage>1959</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2089296</pub-id><pub-id pub-id-type="pmid">35762636</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barenholz</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Doxil — The first FDA-approved nano-drug: lessons learned</article-title><source>Journal of Controlled Release</source><volume>160</volume><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.03.020</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista-Hernández</surname><given-names>LA</given-names></name><name><surname>Gómez-Olivares</surname><given-names>JL</given-names></name><name><surname>Buentello-Volante</surname><given-names>B</given-names></name><name><surname>Bautista-de Lucio</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fibroblasts: the unknown sentinels eliciting immune responses against microorganisms</article-title><source>European Journal of Microbiology and Immunology</source><volume>7</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1556/1886.2017.00009</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>van den Munckhof</surname><given-names>I</given-names></name><name><surname>Nielen</surname><given-names>T</given-names></name><name><surname>Lamfers</surname><given-names>E</given-names></name><name><surname>Dinarello</surname><given-names>C</given-names></name><name><surname>Rutten</surname><given-names>J</given-names></name><name><surname>de Graaf</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Gomes</surname><given-names>MER</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo</article-title><source>Atherosclerosis</source><volume>254</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.10.019</pub-id><pub-id pub-id-type="pmid">27764724</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekkering</surname><given-names>S</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>van der Heijden</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Popa</surname><given-names>CD</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>van Tuijl</surname><given-names>J</given-names></name><name><surname>Netea-Maier</surname><given-names>RT</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Stunnenberg</surname><given-names>H</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic induction of trained immunity through the mevalonate pathway</article-title><source>Cell</source><volume>172</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.025</pub-id><pub-id pub-id-type="pmid">29328908</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A small jab - a big effect: nonspecific immunomodulation by vaccines</article-title><source>Trends in Immunology</source><volume>34</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.it.2013.04.004</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Amenyogbe</surname><given-names>N</given-names></name><name><surname>Björkman</surname><given-names>A</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Fish</surname><given-names>EN</given-names></name><name><surname>Flanagan</surname><given-names>KL</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Kollmann</surname><given-names>TR</given-names></name><name><surname>Kyvik</surname><given-names>KO</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Rod</surname><given-names>NH</given-names></name><name><surname>Schaltz-Buchholzer</surname><given-names>F</given-names></name><name><surname>Shann</surname><given-names>F</given-names></name><name><surname>Selin</surname><given-names>L</given-names></name><name><surname>Thysen</surname><given-names>SM</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Implications of non-specific effects for testing, approving, and regulating vaccines</article-title><source>Drug Safety</source><volume>46</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/s40264-023-01295-3</pub-id><pub-id pub-id-type="pmid">37074598</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernatavicius</surname><given-names>A</given-names></name><name><surname>Šícho</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>APA</given-names></name><name><surname>Hassen</surname><given-names>AK</given-names></name><name><surname>Preuss</surname><given-names>M</given-names></name><name><surname>van Westen</surname><given-names>GJP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Alphafold meets de novo drug design: leveraging structural protein information in multitarget molecular generative models</article-title><source>Journal of Chemical Information and Modeling</source><volume>64</volume><fpage>8113</fpage><lpage>8122</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.4c00309</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blossey</surname><given-names>AM</given-names></name><name><surname>Brückner</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>M</given-names></name><name><surname>Parzmair</surname><given-names>GP</given-names></name><name><surname>Sharma</surname><given-names>H</given-names></name><name><surname>Shaligram</surname><given-names>U</given-names></name><name><surname>Grode</surname><given-names>L</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>VPM1002 as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 in the elderly: a phase 3 randomized, double-blind, placebo-controlled, multicenter clinical study</article-title><source>Clinical Infectious Diseases</source><volume>76</volume><fpage>1304</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac881</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Development and use of machine learning algorithms in vaccine target selection</article-title><source>NPJ Vaccines</source><volume>9</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1038/s41541-023-00795-8</pub-id><pub-id pub-id-type="pmid">38242890</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffen</surname><given-names>K</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>van de Vosse</surname><given-names>E</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Grotenhuis</surname><given-names>AJ</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Chamilos</surname><given-names>G</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004485</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004485</pub-id><pub-id pub-id-type="pmid">25356988</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cafri</surname><given-names>G</given-names></name><name><surname>Gartner</surname><given-names>JJ</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name><name><surname>Hopson</surname><given-names>K</given-names></name><name><surname>Levin</surname><given-names>N</given-names></name><name><surname>Paria</surname><given-names>BC</given-names></name><name><surname>Parkhurst</surname><given-names>MR</given-names></name><name><surname>Yossef</surname><given-names>R</given-names></name><name><surname>Lowery</surname><given-names>FJ</given-names></name><name><surname>Jafferji</surname><given-names>MS</given-names></name><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Goff</surname><given-names>SL</given-names></name><name><surname>McGowan</surname><given-names>CT</given-names></name><name><surname>Seitter</surname><given-names>S</given-names></name><name><surname>Shindorf</surname><given-names>ML</given-names></name><name><surname>Parikh</surname><given-names>A</given-names></name><name><surname>Chatani</surname><given-names>PD</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>5976</fpage><lpage>5988</lpage><pub-id pub-id-type="doi">10.1172/JCI134915</pub-id><pub-id pub-id-type="pmid">33016924</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>JA</given-names></name><name><surname>Jayme</surname><given-names>CC</given-names></name><name><surname>Matsuo</surname><given-names>FS</given-names></name><name><surname>Tedesco</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Chitosan‐gelatin/hydroxyapatite‐based scaffold associated with mesenchymal stem cells differentiate into osteoblasts improves the surface of the bone lesion in mice C57BL/6J</article-title><source>Journal of Applied Polymer Science</source><volume>141</volume><elocation-id>e54978</elocation-id><pub-id pub-id-type="doi">10.1002/app.54978</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Centre Hospitalier Régional d’Orléans</collab></person-group><year iso-8601-date="2024">2024</year><article-title>Assessment of T-Cell Response and In-Vitro Proof-of-Concept of T-Cell Engineering in Chronic End-Stage Kidney Disease Patients</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06474169">https://clinicaltrials.gov/study/NCT06474169</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champion</surname><given-names>JA</given-names></name><name><surname>Mitragotri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Role of target geometry in phagocytosis</article-title><source>PNAS</source><volume>103</volume><fpage>4930</fpage><lpage>4934</lpage><pub-id pub-id-type="doi">10.1073/pnas.0600997103</pub-id><pub-id pub-id-type="pmid">16549762</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation</article-title><source>Nature Immunology</source><volume>20</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0402-5</pub-id><pub-id pub-id-type="pmid">31213716</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>RA</given-names></name><name><surname>Shepardson</surname><given-names>KM</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Manjeri</surname><given-names>GR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van der Veer</surname><given-names>BMJW</given-names></name><name><surname>Deen</surname><given-names>PMT</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Willems</surname><given-names>P</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1250684</elocation-id><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Continuous Atorvastatin Therapy Compared With Intermittent Atorvastatin Therapy for the Effect of LDL-c Level Variability and the Regulation of Trained Immunity</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05790499">https://clinicaltrials.gov/study/NCT05790499</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>RP</given-names></name><name><surname>Rong</surname><given-names>JX</given-names></name><name><surname>Trogan</surname><given-names>E</given-names></name><name><surname>Elmalem</surname><given-names>VI</given-names></name><name><surname>Dansky</surname><given-names>HM</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>24</volume><fpage>1904</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000142808.34602.25</pub-id><pub-id pub-id-type="pmid">15319266</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>RP</given-names></name><name><surname>Edgar</surname><given-names>L</given-names></name><name><surname>Rydén</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Diabetes and metabolic drivers of trained immunity: new therapeutic targets beyond glucose</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>41</volume><fpage>1284</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314211</pub-id><pub-id pub-id-type="pmid">33657881</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname><given-names>A</given-names></name><name><surname>Günther</surname><given-names>P</given-names></name><name><surname>Lauterbach</surname><given-names>MAR</given-names></name><name><surname>Duewell</surname><given-names>P</given-names></name><name><surname>Biswas</surname><given-names>D</given-names></name><name><surname>Pelka</surname><given-names>K</given-names></name><name><surname>Scholz</surname><given-names>CJ</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Haendler</surname><given-names>K</given-names></name><name><surname>Baßler</surname><given-names>K</given-names></name><name><surname>Klee</surname><given-names>K</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Western diet triggers NLRP3-dependent innate immune reprogramming</article-title><source>Cell</source><volume>172</volume><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.013</pub-id><pub-id pub-id-type="pmid">29328911</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>P</given-names></name><name><surname>Nerem</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Bioengineering: 25 years of progress—but still only a beginning</article-title><source>Technology in Society</source><volume>26</volume><fpage>415</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.techsoc.2004.01.008</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Théry</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>30</volume><fpage>255</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-101512-122326</pub-id><pub-id pub-id-type="pmid">25288114</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covarrubias</surname><given-names>S</given-names></name><name><surname>Vollmers</surname><given-names>AC</given-names></name><name><surname>Capili</surname><given-names>A</given-names></name><name><surname>Boettcher</surname><given-names>M</given-names></name><name><surname>Shulkin</surname><given-names>A</given-names></name><name><surname>Correa</surname><given-names>MR</given-names></name><name><surname>Halasz</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>EK</given-names></name><name><surname>O’Briain</surname><given-names>L</given-names></name><name><surname>Vollmers</surname><given-names>C</given-names></name><name><surname>Blau</surname><given-names>J</given-names></name><name><surname>Katzman</surname><given-names>S</given-names></name><name><surname>McManus</surname><given-names>MT</given-names></name><name><surname>Carpenter</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-Throughput CRISPR screening identifies genes involved in macrophage viability and inflammatory pathways</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108541</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108541</pub-id><pub-id pub-id-type="pmid">33378675</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DBT</given-names></name><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Therapeutic genome editing: prospects and challenges</article-title><source>Nature Medicine</source><volume>21</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1038/nm.3793</pub-id><pub-id pub-id-type="pmid">25654603</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W357</fpage><lpage>W364</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz382</pub-id><pub-id pub-id-type="pmid">31106366</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname><given-names>MG</given-names></name><name><surname>Mutharasan</surname><given-names>RK</given-names></name><name><surname>Tripathy</surname><given-names>S</given-names></name><name><surname>McMahon</surname><given-names>KM</given-names></name><name><surname>Thaxton</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery</article-title><source>Advanced Drug Delivery Reviews</source><volume>65</volume><fpage>649</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.07.013</pub-id><pub-id pub-id-type="pmid">22921597</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Laval</surname><given-names>B</given-names></name><name><surname>Maurizio</surname><given-names>J</given-names></name><name><surname>Kandalla</surname><given-names>PK</given-names></name><name><surname>Brisou</surname><given-names>G</given-names></name><name><surname>Simonnet</surname><given-names>L</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Gimenez</surname><given-names>G</given-names></name><name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name><surname>Reinhardt</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Leutz</surname><given-names>A</given-names></name><name><surname>Nadel</surname><given-names>B</given-names></name><name><surname>Bordi</surname><given-names>C</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Sarrazin</surname><given-names>S</given-names></name><name><surname>Sieweke</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>C/EBPβ-dependent epigenetic memory induces trained immunity in hematopoietic stem cells</article-title><source>Cell Stem Cell</source><volume>26</volume><fpage>657</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.01.017</pub-id><pub-id pub-id-type="pmid">32169166</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Fresno</surname><given-names>C</given-names></name><name><surname>García-Arriaza</surname><given-names>J</given-names></name><name><surname>Martínez-Cano</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>748103</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.748103</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Shrestha</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Geller</surname><given-names>AE</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Woeste</surname><given-names>MR</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Chariker</surname><given-names>JH</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tieri</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H-G</given-names></name><name><surname>Rouchka</surname><given-names>EC</given-names></name><name><surname>Mitchell</surname><given-names>R</given-names></name><name><surname>Siskind</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>XG</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis</article-title><source>Nature Immunology</source><volume>24</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01388-8</pub-id><pub-id pub-id-type="pmid">36604547</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>Gresnigt</surname><given-names>MS</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Zwaag</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>RM</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Michelucci</surname><given-names>A</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Stunnenberg</surname><given-names>H</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The itaconate pathway is a central regulatory node linking innate immune tolerance and trained immunity</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.09.003</pub-id><pub-id pub-id-type="pmid">30293776</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>L-H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>H-P</given-names></name><name><surname>Wu</surname><given-names>R-D</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Mu</surname><given-names>M-D</given-names></name><name><surname>Gao</surname><given-names>C-S</given-names></name><name><surname>Weng</surname><given-names>X-Y</given-names></name><name><surname>Ge</surname><given-names>J-B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis</article-title><source>European Heart Journal</source><volume>45</volume><fpage>669</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad787</pub-id><pub-id pub-id-type="pmid">38085922</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting macrophages in cancer immunotherapy</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>127</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-021-00506-6</pub-id><pub-id pub-id-type="pmid">33767177</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname><given-names>L</given-names></name><name><surname>Akbar</surname><given-names>N</given-names></name><name><surname>Braithwaite</surname><given-names>AT</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Gallart-Ayala</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>J</given-names></name><name><surname>Corbin</surname><given-names>AL</given-names></name><name><surname>Khoyratty</surname><given-names>TE</given-names></name><name><surname>Chai</surname><given-names>JT</given-names></name><name><surname>Alkhalil</surname><given-names>M</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Ziberna</surname><given-names>K</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Laurencikiene</surname><given-names>J</given-names></name><name><surname>Crabtree</surname><given-names>MJ</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Wheelock</surname><given-names>CE</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Rydén</surname><given-names>M</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name><name><surname>Carnicer</surname><given-names>R</given-names></name><name><surname>Choudhury</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis</article-title><source>Circulation</source><volume>144</volume><fpage>961</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046464</pub-id><pub-id pub-id-type="pmid">34255973</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Eklöf</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Using Live Vaccines to Induce Beneficial Innate Immune Training and Reduce Systemic Inflammation in COPD Patients</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06257212">https://clinicaltrials.gov/study/NCT06257212</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Kadiry</surname><given-names>AEH</given-names></name><name><surname>Rafei</surname><given-names>M</given-names></name><name><surname>Shammaa</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cell therapy: types, regulation, and clinical benefits</article-title><source>Frontiers in Medicine</source><volume>8</volume><elocation-id>756029</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.756029</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellipilli</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Binzel</surname><given-names>DW</given-names></name><name><surname>Shu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression</article-title><source>Nanomedicine</source><volume>50</volume><elocation-id>102667</elocation-id><pub-id pub-id-type="doi">10.1016/j.nano.2023.102667</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elosegui-Artola</surname><given-names>A</given-names></name><name><surname>Andreu</surname><given-names>I</given-names></name><name><surname>Beedle</surname><given-names>AEM</given-names></name><name><surname>Lezamiz</surname><given-names>A</given-names></name><name><surname>Uroz</surname><given-names>M</given-names></name><name><surname>Kosmalska</surname><given-names>AJ</given-names></name><name><surname>Oria</surname><given-names>R</given-names></name><name><surname>Kechagia</surname><given-names>JZ</given-names></name><name><surname>Rico-Lastres</surname><given-names>P</given-names></name><name><surname>Le Roux</surname><given-names>A-L</given-names></name><name><surname>Shanahan</surname><given-names>CM</given-names></name><name><surname>Trepat</surname><given-names>X</given-names></name><name><surname>Navajas</surname><given-names>D</given-names></name><name><surname>Garcia-Manyes</surname><given-names>S</given-names></name><name><surname>Roca-Cusachs</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Force triggers YAP nuclear entry by regulating transport across nuclear pores</article-title><source>Cell</source><volume>171</volume><fpage>1397</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.008</pub-id><pub-id pub-id-type="pmid">29107331</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engler</surname><given-names>AJ</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Sweeney</surname><given-names>HL</given-names></name><name><surname>Discher</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Matrix elasticity directs stem cell lineage specification</article-title><source>Cell</source><volume>126</volume><fpage>677</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.044</pub-id><pub-id pub-id-type="pmid">16923388</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Fok</surname><given-names>ET</given-names></name><name><surname>Dalla</surname><given-names>E</given-names></name><name><surname>Shibayama</surname><given-names>Y</given-names></name><name><surname>Börner</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>EY</given-names></name><name><surname>Stoychev</surname><given-names>S</given-names></name><name><surname>Imakaev</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments</article-title><source>Nature Genetics</source><volume>51</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0298-2</pub-id><pub-id pub-id-type="pmid">30531872</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The intersection of epigenetics and metabolism in trained immunity</article-title><source>Immunity</source><volume>54</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.10.011</pub-id><pub-id pub-id-type="pmid">33220235</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="web"><person-group person-group-type="author"><collab>FDA</collab></person-group><year iso-8601-date="2022">2022</year><article-title>ZYNTEGLO</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/zynteglo">https://www.fda.gov/vaccines-blood-biologics/zynteglo</ext-link><date-in-citation iso-8601-date="2022-08-17">August 17, 2022</date-in-citation></element-citation></ref><ref id="bib57"><element-citation publication-type="web"><person-group person-group-type="author"><collab>FDA News Release</collab></person-group><year iso-8601-date="2023">2023</year><article-title>FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease">https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease</ext-link><date-in-citation iso-8601-date="2023-12-08">December 8, 2023</date-in-citation></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Cui</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mesenchymal-stem-cell-derived extracellular vesicles mitigate trained immunity in the brain</article-title><source>Frontiers in Bioengineering and Biotechnology</source><volume>8</volume><elocation-id>599058</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.599058</pub-id><pub-id pub-id-type="pmid">33330429</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>AV</given-names></name><name><surname>Kostidis</surname><given-names>S</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Koeken</surname><given-names>VACM</given-names></name><name><surname>Bruno</surname><given-names>M</given-names></name><name><surname>Baydemir</surname><given-names>I</given-names></name><name><surname>Kilic</surname><given-names>G</given-names></name><name><surname>Bulut</surname><given-names>Ö</given-names></name><name><surname>Andriopoulou</surname><given-names>T</given-names></name><name><surname>Spanou</surname><given-names>V</given-names></name><name><surname>Synodinou</surname><given-names>KD</given-names></name><name><surname>Gkavogianni</surname><given-names>T</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Charlotte de Bree</surname><given-names>L</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Matzaraki</surname><given-names>V</given-names></name><name><surname>Koopman</surname><given-names>WJH</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Renieris</surname><given-names>G</given-names></name><name><surname>Giera</surname><given-names>M</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Dimethyl itaconate induces long-term innate immune responses and confers protection against infection</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>112658</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112658</pub-id><pub-id pub-id-type="pmid">37330914</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flavell</surname><given-names>SJ</given-names></name><name><surname>Hou</surname><given-names>TZ</given-names></name><name><surname>Lax</surname><given-names>S</given-names></name><name><surname>Filer</surname><given-names>AD</given-names></name><name><surname>Salmon</surname><given-names>M</given-names></name><name><surname>Buckley</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fibroblasts as novel therapeutic targets in chronic inflammation</article-title><source>British Journal of Pharmacology</source><volume>153 Suppl 1</volume><fpage>S241</fpage><lpage>S246</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707487</pub-id><pub-id pub-id-type="pmid">17965753</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frangoul</surname><given-names>H</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Bhatia</surname><given-names>M</given-names></name><name><surname>Mapara</surname><given-names>M</given-names></name><name><surname>Molinari</surname><given-names>L</given-names></name><name><surname>Wall</surname><given-names>D</given-names></name><name><surname>Liem</surname><given-names>RI</given-names></name><name><surname>Telfer</surname><given-names>P</given-names></name><name><surname>Shah</surname><given-names>AJ</given-names></name><name><surname>Cavazzana</surname><given-names>M</given-names></name><name><surname>Corbacioglu</surname><given-names>S</given-names></name><name><surname>Rondelli</surname><given-names>D</given-names></name><name><surname>Meisel</surname><given-names>R</given-names></name><name><surname>Dedeken</surname><given-names>L</given-names></name><name><surname>Lobitz</surname><given-names>S</given-names></name><name><surname>de Montalembert</surname><given-names>M</given-names></name><name><surname>Steinberg</surname><given-names>MH</given-names></name><name><surname>Walters</surname><given-names>MC</given-names></name><name><surname>Eckrich</surname><given-names>MJ</given-names></name><name><surname>Imren</surname><given-names>S</given-names></name><name><surname>Bower</surname><given-names>L</given-names></name><name><surname>Simard</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xuan</surname><given-names>F</given-names></name><name><surname>Morrow</surname><given-names>PK</given-names></name><name><surname>Hobbs</surname><given-names>WE</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><collab>CLIMB SCD-121 Study Group</collab></person-group><year iso-8601-date="2024">2024</year><article-title>Exagamglogene autotemcel for severe sickle cell disease</article-title><source>The New England Journal of Medicine</source><volume>390</volume><fpage>1649</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2309676</pub-id><pub-id pub-id-type="pmid">38661449</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Freixinet</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients. A Cohort Study</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06341374">https://clinicaltrials.gov/study/NCT06341374</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>B</given-names></name><name><surname>Spatz</surname><given-names>JP</given-names></name><name><surname>Bershadsky</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Environmental sensing through focal adhesions</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>10</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nrm2593</pub-id><pub-id pub-id-type="pmid">19197329</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>AE</given-names></name><name><surname>Shrestha</surname><given-names>R</given-names></name><name><surname>Woeste</surname><given-names>MR</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Andreeva</surname><given-names>K</given-names></name><name><surname>Chariker</surname><given-names>JH</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Tieri</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>CT</given-names></name><name><surname>Mitchell</surname><given-names>RA</given-names></name><name><surname>Zhang</surname><given-names>H-G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Martin Ii</surname><given-names>RCG</given-names></name><name><surname>Rouchka</surname><given-names>EC</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>759</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28407-4</pub-id><pub-id pub-id-type="pmid">35140221</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Tsilika</surname><given-names>M</given-names></name><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Antonakos</surname><given-names>N</given-names></name><name><surname>Kotsaki</surname><given-names>A</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Kyriazopoulou</surname><given-names>E</given-names></name><name><surname>Gkavogianni</surname><given-names>T</given-names></name><name><surname>Adami</surname><given-names>ME</given-names></name><name><surname>Damoraki</surname><given-names>G</given-names></name><name><surname>Koufargyris</surname><given-names>P</given-names></name><name><surname>Karageorgos</surname><given-names>A</given-names></name><name><surname>Bolanou</surname><given-names>A</given-names></name><name><surname>Koenen</surname><given-names>H</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Droggiti</surname><given-names>DI</given-names></name><name><surname>Renieris</surname><given-names>G</given-names></name><name><surname>Papadopoulos</surname><given-names>A</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activate: randomized clinical trial of bcg vaccination against infection in the elderly</article-title><source>Cell</source><volume>183</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.051</pub-id><pub-id pub-id-type="pmid">32941801</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez Perdiguero</surname><given-names>E</given-names></name><name><surname>Klapproth</surname><given-names>K</given-names></name><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Busch</surname><given-names>K</given-names></name><name><surname>Azzoni</surname><given-names>E</given-names></name><name><surname>Crozet</surname><given-names>L</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Trouillet</surname><given-names>C</given-names></name><name><surname>de Bruijn</surname><given-names>MF</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Rodewald</surname><given-names>H-R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors</article-title><source>Nature</source><volume>518</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature13989</pub-id><pub-id pub-id-type="pmid">25470051</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodridge</surname><given-names>HS</given-names></name><name><surname>Ahmed</surname><given-names>SS</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>Kollmann</surname><given-names>TR</given-names></name><name><surname>Levy</surname><given-names>O</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Harnessing the beneficial heterologous effects of vaccination</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>392</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.43</pub-id><pub-id pub-id-type="pmid">27157064</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>C</given-names></name><name><surname>Fernandes</surname><given-names>FC</given-names></name><name><surname>Franco</surname><given-names>OL</given-names></name><name><surname>de la Fuente-Nunez</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Leveraging large language models for peptide antibiotic design</article-title><source>Cell Reports. Physical Science</source><volume>6</volume><elocation-id>102359</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrp.2024.102359</pub-id><pub-id pub-id-type="pmid">39949833</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenther</surname><given-names>C</given-names></name><name><surname>Faisal</surname><given-names>I</given-names></name><name><surname>Fusciello</surname><given-names>M</given-names></name><name><surname>Sokolova</surname><given-names>M</given-names></name><name><surname>Harjunpää</surname><given-names>H</given-names></name><name><surname>Ilander</surname><given-names>M</given-names></name><name><surname>Tallberg</surname><given-names>R</given-names></name><name><surname>Vartiainen</surname><given-names>MK</given-names></name><name><surname>Alon</surname><given-names>R</given-names></name><name><surname>Gonzalez-Granado</surname><given-names>JM</given-names></name><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Fagerholm</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>β2-integrin adhesion regulates dendritic cell epigenetic and transcriptional landscapes to restrict dendritic cell maturation and tumor rejection</article-title><source>Cancer Immunology Research</source><volume>9</volume><fpage>1354</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-21-0094</pub-id><pub-id pub-id-type="pmid">34561280</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackett</surname><given-names>T-L</given-names></name><name><surname>Vriesde</surname><given-names>NRTF</given-names></name><name><surname>Al-Fouadi</surname><given-names>M</given-names></name><name><surname>Mostaco-Guidolin</surname><given-names>L</given-names></name><name><surname>Maftoun</surname><given-names>D</given-names></name><name><surname>Hsieh</surname><given-names>A</given-names></name><name><surname>Coxson</surname><given-names>N</given-names></name><name><surname>Usman</surname><given-names>K</given-names></name><name><surname>Sin</surname><given-names>DD</given-names></name><name><surname>Booth</surname><given-names>S</given-names></name><name><surname>Osei</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of the dynamic lung extracellular matrix environment on fibroblast morphology and inflammation</article-title><source>Cells</source><volume>11</volume><elocation-id>185</elocation-id><pub-id pub-id-type="doi">10.3390/cells11020185</pub-id><pub-id pub-id-type="pmid">35053300</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harjunpää</surname><given-names>H</given-names></name><name><surname>Somermäki</surname><given-names>R</given-names></name><name><surname>Saldo Rubio</surname><given-names>G</given-names></name><name><surname>Fusciello</surname><given-names>M</given-names></name><name><surname>Feola</surname><given-names>S</given-names></name><name><surname>Faisal</surname><given-names>I</given-names></name><name><surname>Nieminen</surname><given-names>AI</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Llort Asens</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Eriksson</surname><given-names>O</given-names></name><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Fagerholm</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses</article-title><source>Oncoimmunology</source><volume>13</volume><elocation-id>2369373</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2024.2369373</pub-id><pub-id pub-id-type="pmid">38915784</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>M</given-names></name><name><surname>Mülsch</surname><given-names>A</given-names></name><name><surname>Bassenge</surname><given-names>E</given-names></name><name><surname>Förstermann</surname><given-names>U</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Subcellular localization and characterization of nitric oxide synthase(s) in endothelial cells: physiological implications</article-title><source>The Biochemical Journal</source><volume>299 (Pt 1)</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1042/bj2990247</pub-id><pub-id pub-id-type="pmid">7513152</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Borggrewe</surname><given-names>M</given-names></name><name><surname>van Weering</surname><given-names>HRJ</given-names></name><name><surname>Brummer</surname><given-names>ML</given-names></name><name><surname>Nijboer</surname><given-names>TW</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Boddeke</surname><given-names>EWGM</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><name><surname>Eggen</surname><given-names>BJL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Systemic administration of β-glucan induces immune training in microglia</article-title><source>Journal of Neuroinflammation</source><volume>18</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-021-02103-4</pub-id><pub-id pub-id-type="pmid">33618716</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>S-J</given-names></name><name><surname>Han</surname><given-names>WM</given-names></name><name><surname>Szczesny</surname><given-names>SE</given-names></name><name><surname>Cosgrove</surname><given-names>BD</given-names></name><name><surname>Elliott</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Duncan</surname><given-names>RL</given-names></name><name><surname>Mauck</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanically induced chromatin condensation requires cellular contractility in mesenchymal stem cells</article-title><source>Biophysical Journal</source><volume>111</volume><fpage>864</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2016.07.006</pub-id><pub-id pub-id-type="pmid">27558729</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Soares-Weiser</surname><given-names>K</given-names></name><name><surname>López-López</surname><given-names>JA</given-names></name><name><surname>Kakourou</surname><given-names>A</given-names></name><name><surname>Chaplin</surname><given-names>K</given-names></name><name><surname>Christensen</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>NK</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>Reingold</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review</article-title><source>BMJ</source><volume>355</volume><elocation-id>i5170</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.i5170</pub-id><pub-id pub-id-type="pmid">27737834</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoagland</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1944">1944</year><article-title>Adventures in biological engineering</article-title><source>Science</source><volume>100</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1126/science.100.2587.63</pub-id><pub-id pub-id-type="pmid">17806403</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Sandalova</surname><given-names>E</given-names></name><name><surname>Low</surname><given-names>D</given-names></name><name><surname>Gehring</surname><given-names>AJ</given-names></name><name><surname>Fieni</surname><given-names>S</given-names></name><name><surname>Amadei</surname><given-names>B</given-names></name><name><surname>Urbani</surname><given-names>S</given-names></name><name><surname>Chong</surname><given-names>Y-S</given-names></name><name><surname>Guccione</surname><given-names>E</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Trained immunity in newborn infants of HBV-infected mothers</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6588</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7588</pub-id><pub-id pub-id-type="pmid">25807344</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hood</surname><given-names>JD</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of integrins in cell invasion and migration</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/nrc727</pub-id><pub-id pub-id-type="pmid">12635172</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotz</surname><given-names>C</given-names></name><name><surname>Wagenaar</surname><given-names>TR</given-names></name><name><surname>Gieseke</surname><given-names>F</given-names></name><name><surname>Bangari</surname><given-names>DS</given-names></name><name><surname>Callahan</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Diekmann</surname><given-names>J</given-names></name><name><surname>Diken</surname><given-names>M</given-names></name><name><surname>Grunwitz</surname><given-names>C</given-names></name><name><surname>Hebert</surname><given-names>A</given-names></name><name><surname>Hsu</surname><given-names>K</given-names></name><name><surname>Bernardo</surname><given-names>M</given-names></name><name><surname>Karikó</surname><given-names>K</given-names></name><name><surname>Kreiter</surname><given-names>S</given-names></name><name><surname>Kuhn</surname><given-names>AN</given-names></name><name><surname>Levit</surname><given-names>M</given-names></name><name><surname>Malkova</surname><given-names>N</given-names></name><name><surname>Masciari</surname><given-names>S</given-names></name><name><surname>Pollard</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Ryan</surname><given-names>S</given-names></name><name><surname>Selmi</surname><given-names>A</given-names></name><name><surname>Schlereth</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Tillmann</surname><given-names>B</given-names></name><name><surname>Tolstykh</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>W</given-names></name><name><surname>Wicke</surname><given-names>L</given-names></name><name><surname>Witzel</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>YA</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Lager</surname><given-names>J</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Wiederschain</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabc7804</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abc7804</pub-id><pub-id pub-id-type="pmid">34516826</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Marks</surname><given-names>E</given-names></name><name><surname>Schneider</surname><given-names>JJ</given-names></name><name><surname>Keely</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue</article-title><source>Nanomedicine</source><volume>11</volume><fpage>1117</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2015.02.018</pub-id><pub-id pub-id-type="pmid">25784453</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ideker</surname><given-names>T</given-names></name><name><surname>Winslow</surname><given-names>LR</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Bioengineering and Systems Biology</article-title><source>Annals of Biomedical Engineering</source><volume>34</volume><fpage>1226</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1007/s10439-006-9119-3</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Inmunotek</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A Phase I/II Randomized, Prospective, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05208060">https://clinicaltrials.gov/study/NCT05208060</ext-link><date-in-citation iso-8601-date="2024-05-15">May 15, 2024</date-in-citation></element-citation></ref><ref id="bib83"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Institut Pasteur</collab></person-group><year iso-8601-date="2024">2024</year><article-title>Description of the Immune Response to Yellow Fever Vaccination</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06718127">https://clinicaltrials.gov/study/NCT06718127</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>M</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>JK</given-names></name><name><surname>Cheong</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer</article-title><source>Nature Biomedical Engineering</source><volume>5</volume><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00657-x</pub-id><pub-id pub-id-type="pmid">33288878</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>VA</given-names></name><name><surname>Scott</surname><given-names>GB</given-names></name><name><surname>Rose</surname><given-names>AMS</given-names></name><name><surname>Scott</surname><given-names>KJ</given-names></name><name><surname>Migneco</surname><given-names>G</given-names></name><name><surname>Keller</surname><given-names>B</given-names></name><name><surname>Reilly</surname><given-names>K</given-names></name><name><surname>Donnelly</surname><given-names>O</given-names></name><name><surname>Peach</surname><given-names>H</given-names></name><name><surname>Dewar</surname><given-names>D</given-names></name><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Pandha</surname><given-names>H</given-names></name><name><surname>Samson</surname><given-names>A</given-names></name><name><surname>Vile</surname><given-names>RG</given-names></name><name><surname>Melcher</surname><given-names>AA</given-names></name><name><surname>Errington-Mais</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Potentiating oncolytic virus-induced immune-mediated tumor cell killing using histone deacetylase inhibition</article-title><source>Molecular Therapy</source><volume>27</volume><fpage>1139</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.04.008</pub-id><pub-id pub-id-type="pmid">31053413</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Jiayuan</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Multicenter, Randomized, Controlled Clinical Trial of Tissue-Engineered Skin Grafts With Autologous Scar Dermal Scaffolds for the Repair of Hypertrophic Scars</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04389164">https://clinicaltrials.gov/study/NCT04389164</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>SP</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Pierre</surname><given-names>MJ</given-names></name><name><surname>Alsalih</surname><given-names>L</given-names></name><name><surname>Lipsey</surname><given-names>C</given-names></name><name><surname>Traore</surname><given-names>Z</given-names></name><name><surname>Balcom-Luker</surname><given-names>S</given-names></name><name><surname>Bradfield</surname><given-names>CJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Markowitz</surname><given-names>TE</given-names></name><name><surname>Smelkinson</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Fraser</surname><given-names>IDC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection</article-title><source>Cell Reports</source><volume>41</volume><elocation-id>111441</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111441</pub-id><pub-id pub-id-type="pmid">36179680</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DL</given-names></name><name><surname>Hallström</surname><given-names>GF</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Locke</surname><given-names>RC</given-names></name><name><surname>Evans</surname><given-names>MK</given-names></name><name><surname>Bonnevie</surname><given-names>ED</given-names></name><name><surname>Srikumar</surname><given-names>A</given-names></name><name><surname>Leahy</surname><given-names>TP</given-names></name><name><surname>Nijsure</surname><given-names>MP</given-names></name><name><surname>Boerckel</surname><given-names>JD</given-names></name><name><surname>Mauck</surname><given-names>RL</given-names></name><name><surname>Dyment</surname><given-names>NA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mechanoepigenetic regulation of extracellular matrix homeostasis via Yap and Taz</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2211947120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2211947120</pub-id><pub-id pub-id-type="pmid">37216538</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hatzioannou</surname><given-names>A</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Hagag</surname><given-names>E</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Has</surname><given-names>C</given-names></name><name><surname>Dietz</surname><given-names>S</given-names></name><name><surname>de Jesus Domingues</surname><given-names>AM</given-names></name><name><surname>Nati</surname><given-names>M</given-names></name><name><surname>Sormendi</surname><given-names>S</given-names></name><name><surname>Neuwirth</surname><given-names>A</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Ziogas</surname><given-names>A</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Subramanian</surname><given-names>P</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>KJ</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Verginis</surname><given-names>P</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate immune training of granulopoiesis promotes anti-tumor activity</article-title><source>Cell</source><volume>183</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.058</pub-id><pub-id pub-id-type="pmid">33125892</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkal</surname><given-names>A</given-names></name><name><surname>Pradhan</surname><given-names>R</given-names></name><name><surname>Kadian</surname><given-names>S</given-names></name><name><surname>Manik</surname><given-names>G</given-names></name><name><surname>Packirisamy</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biofunctionalized graphene quantum dots based fluorescent biosensor toward efficient detection of small cell lung cancer</article-title><source>ACS Applied Bio Materials</source><volume>3</volume><fpage>4922</fpage><lpage>4932</lpage><pub-id pub-id-type="doi">10.1021/acsabm.0c00427</pub-id><pub-id pub-id-type="pmid">35021736</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>J</given-names></name><name><surname>Graf</surname><given-names>BA</given-names></name><name><surname>Leung</surname><given-names>EC</given-names></name><name><surname>Pollock</surname><given-names>SJ</given-names></name><name><surname>Koumas</surname><given-names>L</given-names></name><name><surname>Reddy</surname><given-names>SY</given-names></name><name><surname>Blieden</surname><given-names>TM</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Phipps</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Fibroblasts as sentinel cells: role of the CDcd40-CDcd40 ligand system in fibroblast activation and lung inflammation and fibrosis</article-title><source>Chest</source><volume>120</volume><fpage>53S</fpage><lpage>55S</lpage><pub-id pub-id-type="doi">10.1378/chest.120.1_suppl.s53</pub-id><pub-id pub-id-type="pmid">11451915</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>HL</given-names></name><name><surname>Shalhout</surname><given-names>SZ</given-names></name><name><surname>Iodice</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Talimogene laherparepvec: moving from first-in-class to best-in-class</article-title><source>Frontiers in Molecular Biosciences</source><volume>9</volume><elocation-id>834841</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2022.834841</pub-id><pub-id pub-id-type="pmid">35274007</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mendonça</surname><given-names>LE</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><name><surname>Tzelepis</surname><given-names>F</given-names></name><name><surname>Pernet</surname><given-names>E</given-names></name><name><surname>Dumaine</surname><given-names>A</given-names></name><name><surname>Grenier</surname><given-names>J-C</given-names></name><name><surname>Mailhot-Léonard</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Belle</surname><given-names>J</given-names></name><name><surname>Besla</surname><given-names>R</given-names></name><name><surname>Mazer</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>IL</given-names></name><name><surname>Nijnik</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><volume>172</volume><fpage>176</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Choi</surname><given-names>WI</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Tae</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier</article-title><source>Biomaterials</source><volume>34</volume><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.09.047</pub-id><pub-id pub-id-type="pmid">23122677</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NG</given-names></name><name><surname>Gumbiner</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway</article-title><source>The Journal of Cell Biology</source><volume>210</volume><fpage>503</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1083/jcb.201501025</pub-id><pub-id pub-id-type="pmid">26216901</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Preijers</surname><given-names>F</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>C</given-names></name><name><surname>van Loenhout</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes</article-title><source>PNAS</source><volume>109</volume><fpage>17537</fpage><lpage>17542</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id><pub-id pub-id-type="pmid">22988082</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>HR</given-names></name><name><surname>Ketter</surname><given-names>E</given-names></name><name><surname>Ung</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Ajit</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Ip</surname><given-names>KM</given-names></name><name><surname>Chiang</surname><given-names>C-Y</given-names></name><name><surname>Barreiro</surname><given-names>L</given-names></name><name><surname>Esser-Kahn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>High-throughput screen identifies non inflammatory small molecule inducers of trained immunity</article-title><source>PNAS</source><volume>121</volume><elocation-id>e2400413121</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2400413121</pub-id><pub-id pub-id-type="pmid">38976741</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koelwyn</surname><given-names>GJ</given-names></name><name><surname>Newman</surname><given-names>AAC</given-names></name><name><surname>Afonso</surname><given-names>MS</given-names></name><name><surname>van Solingen</surname><given-names>C</given-names></name><name><surname>Corr</surname><given-names>EM</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Albers</surname><given-names>KB</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Narke</surname><given-names>D</given-names></name><name><surname>Schlegel</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Shanley</surname><given-names>LC</given-names></name><name><surname>Barrett</surname><given-names>TJ</given-names></name><name><surname>Rahman</surname><given-names>K</given-names></name><name><surname>Mezzano</surname><given-names>V</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Park</surname><given-names>DS</given-names></name><name><surname>Newman</surname><given-names>JD</given-names></name><name><surname>Quail</surname><given-names>DF</given-names></name><name><surname>Nelson</surname><given-names>ER</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myocardial infarction accelerates breast cancer via innate immune reprogramming</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1452</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0964-7</pub-id><pub-id pub-id-type="pmid">32661390</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Kulkarni</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chemuturi</surname><given-names>N</given-names></name><name><surname>Shah</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles</article-title><source>Advanced Drug Delivery Reviews</source><volume>194</volume><elocation-id>114708</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2023.114708</pub-id><pub-id pub-id-type="pmid">36682420</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>SB</given-names></name><name><surname>Cowley</surname><given-names>CJ</given-names></name><name><surname>Sajjath</surname><given-names>SM</given-names></name><name><surname>Barrows</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Carroll</surname><given-names>TS</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Establishment, maintenance, and recall of inflammatory memory</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>1758</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.07.001</pub-id><pub-id pub-id-type="pmid">34320411</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>RC</given-names></name><name><surname>Maus</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Recent advances and discoveries in the mechanisms and functions of CAR T cells</article-title><source>Nature Reviews. Cancer</source><volume>21</volume><fpage>145</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-00323-z</pub-id><pub-id pub-id-type="pmid">33483715</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>MKD</given-names></name><name><surname>Wimmers</surname><given-names>F</given-names></name><name><surname>Arunachalam</surname><given-names>PS</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Fox</surname><given-names>CB</given-names></name><name><surname>Tomai</surname><given-names>M</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A molecular atlas of innate immunity to adjuvanted and live attenuated vaccines, in mice</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>549</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28197-9</pub-id><pub-id pub-id-type="pmid">35087093</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Ahn</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>The role of NLRP3 inflammasomes in trained immunity</article-title><source>Frontiers in Bioscience</source><volume>28</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.31083/j.fbl2809210</pub-id><pub-id pub-id-type="pmid">37796716</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Medhi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ha</surname><given-names>IH</given-names></name><name><surname>Nam</surname><given-names>KT</given-names></name><name><surname>Ploegh</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Selective targeting of nanobody-modified gold nanoparticles to distinct cell types</article-title><source>ACS Applied Materials &amp; Interfaces</source><volume>15</volume><fpage>59258</fpage><lpage>59268</lpage><pub-id pub-id-type="doi">10.1021/acsami.3c16829</pub-id><pub-id pub-id-type="pmid">38091481</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis</article-title><source>Stem Cell Research &amp; Therapy</source><volume>15</volume><elocation-id>290</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-024-03891-1</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>A</given-names></name><name><surname>Tisdale</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A new frontier: FDA approvals for gene therapy in sickle cell disease</article-title><source>Molecular Therapy</source><volume>32</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2024.01.015</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>P</given-names></name><name><surname>You</surname><given-names>Z-H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In silico prediction of drug-target interaction networks based on drug chemical structure and protein sequences</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>11174</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-10724-0</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Gelinsky</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tailoring materials for modulation of macrophage fate</article-title><source>Advanced Materials</source><volume>33</volume><elocation-id>e4172</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202004172</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Saha</surname><given-names>G</given-names></name><name><surname>Kalafati</surname><given-names>L</given-names></name><name><surname>Ioannidis</surname><given-names>C</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Maladaptive innate immune training of myelopoiesis links inflammatory comorbidities</article-title><source>Cell</source><volume>185</volume><fpage>1709</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.03.043</pub-id><pub-id pub-id-type="pmid">35483374</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>AP-S</given-names></name><name><surname>Tian</surname><given-names>XY</given-names></name><name><surname>Chan</surname><given-names>H-F</given-names></name><name><surname>Chung</surname><given-names>AC-K</given-names></name><name><surname>Cheng</surname><given-names>JC-Y</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>WY-W</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Sirt3 mediates the benefits of exercise on bone in aged mice</article-title><source>Cell Death and Differentiation</source><volume>30</volume><fpage>152</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-01053-5</pub-id><pub-id pub-id-type="pmid">36153410</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>P-F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>CRISPR/Cas9 therapeutics: progress and prospects</article-title><source>Signal Transduction and Targeted Therapy</source><volume>8</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-023-01309-7</pub-id><pub-id pub-id-type="pmid">36646687</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>O</given-names></name><name><surname>Sobreira</surname><given-names>DR</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>R-T</given-names></name><name><surname>Miao</surname><given-names>B</given-names></name><name><surname>Sakabe</surname><given-names>NJ</given-names></name><name><surname>Krause</surname><given-names>MD</given-names></name><name><surname>Kaikkonen</surname><given-names>MU</given-names></name><name><surname>Romanoski</surname><given-names>CE</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Mechanosensitive super-enhancers regulate genes linked to atherosclerosis in endothelial cells</article-title><source>The Journal of Cell Biology</source><volume>223</volume><elocation-id>e202211125</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202211125</pub-id><pub-id pub-id-type="pmid">38231044</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>In silico methods for identification of potential active sites of therapeutic targets</article-title><source>Molecules</source><volume>27</volume><elocation-id>7103</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27207103</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Libmeldy</collab></person-group><year iso-8601-date="2020">2020</year><article-title>European Medicines Agency</article-title><ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy">https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy</ext-link><date-in-citation iso-8601-date="2025-07-04">July 4, 2025</date-in-citation></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions</article-title><source>Journal of Controlled Release</source><volume>343</volume><fpage>657</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.12.025</pub-id><pub-id pub-id-type="pmid">34954252</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2024">2024a</year><article-title>Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems</article-title><source>ACS Nano</source><volume>18</volume><fpage>20861</fpage><lpage>20885</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c02380</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>Y-X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Nie</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2024">2024b</year><article-title>Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity</article-title><source>Nature Nanotechnology</source><volume>19</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01553-6</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems</article-title><source>Frontiers in Nutrition</source><volume>8</volume><elocation-id>783831</elocation-id><pub-id pub-id-type="doi">10.3389/fnut.2021.783831</pub-id><pub-id pub-id-type="pmid">34926557</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Controllable Protein Design by Prefix-Tuning Protein Language Models</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.12.03.569747</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties</article-title><source>Drug Delivery and Translational Research</source><volume>11</volume><fpage>1218</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1007/s13346-020-00849-7</pub-id><pub-id pub-id-type="pmid">32946043</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Amplification of Autologous Epidermal Cells to Repair Large Area Deep Wounds</article-title><source>Clinicaltrials.gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05882110">https://clinicaltrials.gov/study/NCT05882110</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madani</surname><given-names>A</given-names></name><name><surname>Krause</surname><given-names>B</given-names></name><name><surname>Greene</surname><given-names>ER</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>Mohr</surname><given-names>BP</given-names></name><name><surname>Holton</surname><given-names>JM</given-names></name><name><surname>Olmos</surname><given-names>JL</given-names><suffix>Jr</suffix></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>ZZ</given-names></name><name><surname>Socher</surname><given-names>R</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name><name><surname>Naik</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Large language models generate functional protein sequences across diverse families</article-title><source>Nature Biotechnology</source><volume>41</volume><fpage>1099</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01618-2</pub-id><pub-id pub-id-type="pmid">36702895</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallick</surname><given-names>I</given-names></name><name><surname>Panchal</surname><given-names>P</given-names></name><name><surname>Kadam</surname><given-names>S</given-names></name><name><surname>Mohite</surname><given-names>P</given-names></name><name><surname>Scheele</surname><given-names>J</given-names></name><name><surname>Seiz</surname><given-names>W</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>OP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>In-silico identification and prioritization of therapeutic targets of asthma</article-title><source>Scientific Reports</source><volume>13</volume><elocation-id>15706</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-42803-w</pub-id><pub-id pub-id-type="pmid">37735578</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>TS</given-names></name><name><surname>Kain</surname><given-names>B</given-names></name><name><surname>Burchill</surname><given-names>MA</given-names></name><name><surname>Danis</surname><given-names>E</given-names></name><name><surname>Lucas</surname><given-names>ED</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Cowan</surname><given-names>CM</given-names></name><name><surname>Schleicher</surname><given-names>WE</given-names></name><name><surname>Patel</surname><given-names>SB</given-names></name><name><surname>Tran</surname><given-names>BT</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Goodspeed</surname><given-names>A</given-names></name><name><surname>Ferrara</surname><given-names>S</given-names></name><name><surname>Bevers</surname><given-names>S</given-names></name><name><surname>Jirón Tamburini</surname><given-names>BA</given-names></name><name><surname>Roede</surname><given-names>JR</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Pietras</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A distinct metabolic and epigenetic state drives trained immunity in HSC-derived macrophages from autoimmune mice</article-title><source>Cell Stem Cell</source><volume>31</volume><fpage>1630</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2024.09.010</pub-id><pub-id pub-id-type="pmid">39413777</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minocha</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nanostructure system: liposome – a bioactive carrier in drug delivery systems</article-title><source>Materials Today</source><volume>69</volume><fpage>614</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.matpr.2022.09.494</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranti</surname><given-names>CK</given-names></name><name><surname>Brugge</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Sensing the environment: a historical perspective on integrin signal transduction</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>E83</fpage><lpage>E90</lpage><pub-id pub-id-type="doi">10.1038/ncb0402-e83</pub-id><pub-id pub-id-type="pmid">11944041</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitragotri</surname><given-names>S</given-names></name><name><surname>Lahann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Physical approaches to biomaterial design</article-title><source>Nature Materials</source><volume>8</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nmat2344</pub-id><pub-id pub-id-type="pmid">19096389</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Ruppova</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>LS</given-names></name><name><surname>Grzybek</surname><given-names>M</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Eugster</surname><given-names>A</given-names></name><name><surname>Troullinaki</surname><given-names>M</given-names></name><name><surname>Palladini</surname><given-names>A</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Isermann</surname><given-names>B</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Petzold</surname><given-names>A</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Zamboni</surname><given-names>N</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Coskun</surname><given-names>Ü</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modulation of myelopoiesis progenitors is an integral component of trained immunity</article-title><source>Cell</source><volume>172</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.034</pub-id><pub-id pub-id-type="pmid">29328910</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>β-glucan induces protective trained immunity against <italic>Mycobacterium tuberculosis</italic> infection: a key role for IL-1</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107634</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107634</pub-id><pub-id pub-id-type="pmid">32433977</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Folkman</surname><given-names>L</given-names></name><name><surname>Ter Horst</surname><given-names>R</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Barreca</surname><given-names>D</given-names></name><name><surname>Schuster</surname><given-names>LC</given-names></name><name><surname>Fife</surname><given-names>V</given-names></name><name><surname>Matzaraki</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Reichl</surname><given-names>S</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Koeken</surname><given-names>VACM</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Dijkstra</surname><given-names>H</given-names></name><name><surname>Lemmers</surname><given-names>H</given-names></name><name><surname>van Cranenbroek</surname><given-names>B</given-names></name><name><surname>van Rijssen</surname><given-names>E</given-names></name><name><surname>Koenen</surname><given-names>HJPM</given-names></name><name><surname>Joosten</surname><given-names>I</given-names></name><name><surname>Xu</surname><given-names>C-J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity</article-title><source>Immunity</source><volume>57</volume><fpage>171</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.12.005</pub-id><pub-id pub-id-type="pmid">38198850</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Therapeutic targeting of trained immunity</article-title><source>Nature Reviews. Drug Discovery</source><volume>18</volume><fpage>553</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0025-4</pub-id><pub-id pub-id-type="pmid">30967658</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Larsen</surname><given-names>SB</given-names></name><name><surname>Gomez</surname><given-names>NC</given-names></name><name><surname>Alaverdyan</surname><given-names>K</given-names></name><name><surname>Sendoel</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Polak</surname><given-names>L</given-names></name><name><surname>Kulukian</surname><given-names>A</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammatory memory sensitizes skin epithelial stem cells to tissue damage</article-title><source>Nature</source><volume>550</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1038/nature24271</pub-id><pub-id pub-id-type="pmid">29045388</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inflammatory memory and tissue adaptation in sickness and in health</article-title><source>Nature</source><volume>607</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04919-3</pub-id><pub-id pub-id-type="pmid">35831602</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardone</surname><given-names>G</given-names></name><name><surname>Oliver-De La Cruz</surname><given-names>J</given-names></name><name><surname>Vrbsky</surname><given-names>J</given-names></name><name><surname>Martini</surname><given-names>C</given-names></name><name><surname>Pribyl</surname><given-names>J</given-names></name><name><surname>Skládal</surname><given-names>P</given-names></name><name><surname>Pešl</surname><given-names>M</given-names></name><name><surname>Caluori</surname><given-names>G</given-names></name><name><surname>Pagliari</surname><given-names>S</given-names></name><name><surname>Martino</surname><given-names>F</given-names></name><name><surname>Maceckova</surname><given-names>Z</given-names></name><name><surname>Hajduch</surname><given-names>M</given-names></name><name><surname>Sanz-Garcia</surname><given-names>A</given-names></name><name><surname>Pugno</surname><given-names>NM</given-names></name><name><surname>Stokin</surname><given-names>GB</given-names></name><name><surname>Forte</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP regulates cell mechanics by controlling focal adhesion assembly</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15321</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15321</pub-id><pub-id pub-id-type="pmid">28504269</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Nature</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Reflections on bioengineering’s disruptiveness</article-title><source>Nature Reviews Bioengineering</source><volume>1</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1038/s44222-023-00051-7</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nava</surname><given-names>MM</given-names></name><name><surname>Miroshnikova</surname><given-names>YA</given-names></name><name><surname>Biggs</surname><given-names>LC</given-names></name><name><surname>Whitefield</surname><given-names>DB</given-names></name><name><surname>Metge</surname><given-names>F</given-names></name><name><surname>Boucas</surname><given-names>J</given-names></name><name><surname>Vihinen</surname><given-names>H</given-names></name><name><surname>Jokitalo</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>García Arcos</surname><given-names>JM</given-names></name><name><surname>Hoffmann</surname><given-names>B</given-names></name><name><surname>Merkel</surname><given-names>R</given-names></name><name><surname>Niessen</surname><given-names>CM</given-names></name><name><surname>Dahl</surname><given-names>KN</given-names></name><name><surname>Wickström</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Heterochromatin-driven nuclear softening protects the genome against mechanical stress-induced damage</article-title><source>Cell</source><volume>181</volume><fpage>800</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.052</pub-id><pub-id pub-id-type="pmid">32302590</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Nerem</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The Emergence of Bioengineering. National Academy of Engineering Website</article-title><ext-link ext-link-type="uri" xlink:href="https://www.nae.edu/7543/TheEmergenceofBioengineering">https://www.nae.edu/7543/TheEmergenceofBioengineering</ext-link><date-in-citation iso-8601-date="1997-12-01">December 1, 1997</date-in-citation></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Trained immunity: a memory for innate host defense</article-title><source>Cell Host &amp; Microbe</source><volume>9</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.04.006</pub-id><pub-id pub-id-type="pmid">21575907</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Mills</surname><given-names>KHG</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trained immunity: a program of innate immune memory in health and disease</article-title><source>Science</source><volume>352</volume><elocation-id>aaf1098</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaf1098</pub-id><pub-id pub-id-type="pmid">27102489</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Trained immunity and local innate immune memory in the lung</article-title><source>Cell</source><volume>175</volume><fpage>1463</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.007</pub-id><pub-id pub-id-type="pmid">30500533</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Stabell Benn</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Mo</surname><given-names>W</given-names></name><name><surname>Miron</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Macrophages modulate stiffness-related foreign body responses through plasma membrane deformation</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2213837120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2213837120</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niazi</surname><given-names>SK</given-names></name><name><surname>Mariam</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Computer-aided drug design and drug discovery: a prospective analysis</article-title><source>Pharmaceuticals</source><volume>17</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/ph17010022</pub-id><pub-id pub-id-type="pmid">38256856</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Habibi</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>S-Y</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Davar</surname><given-names>R</given-names></name><name><surname>Megchelenbrink</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Zwaag</surname><given-names>J</given-names></name><name><surname>Matarese</surname><given-names>F</given-names></name><name><surname>van Heeringen</surname><given-names>SJ</given-names></name><name><surname>Janssen-Megens</surname><given-names>EM</given-names></name><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Keramati</surname><given-names>F</given-names></name><name><surname>Schoonenberg</surname><given-names>V</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>β-glucan reverses the epigenetic state of LPS-Induced Immunological Tolerance</article-title><source>Cell</source><volume>167</volume><fpage>1354</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.034</pub-id><pub-id pub-id-type="pmid">27863248</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>I remember you: epigenetic priming in epithelial stem cells</article-title><source>Immunity</source><volume>47</volume><fpage>1019</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.12.005</pub-id><pub-id pub-id-type="pmid">29262345</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><name><surname>Madsen</surname><given-names>JC</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Duivenvoorden</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Trained immunity - basic concepts and contributions to immunopathology</article-title><source>Nature Reviews. Nephrology</source><volume>19</volume><fpage>23</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/s41581-022-00633-5</pub-id><pub-id pub-id-type="pmid">36253509</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>O’Farrell</surname><given-names>A</given-names></name><name><surname>Niu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Eyndhoven</surname><given-names>LC</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Innate Immune Memory Is Stimulus Specific</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2025.01.22.634275</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>BMJ</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Intestinal stromal cells in mucosal immunity and homeostasis</article-title><source>Mucosal Immunology</source><volume>6</volume><fpage>224</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.125</pub-id><pub-id pub-id-type="pmid">23235744</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>BMJ</given-names></name><name><surname>Steevels</surname><given-names>TAM</given-names></name><name><surname>Dudek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD90(+) stromal cells are non-professional innate immune effectors of the human colonic mucosa</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>307</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00307</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>BMJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inflammation, innate immunity, and the intestinal stromal cell niche: opportunities and challenges</article-title><source>Frontiers in Immunology</source><volume>6</volume><elocation-id>319</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2015.00319</pub-id><pub-id pub-id-type="pmid">26150817</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Alginate-gelatin hydrogel promotes the neurogenic differentiation potential of bone marrow CD117<sup>+</sup> hematopoietic stem cells</article-title><source>Regenerative Therapy</source><volume>26</volume><fpage>1030</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/j.reth.2024.10.009</pub-id><pub-id pub-id-type="pmid">39569341</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poletti</surname><given-names>V</given-names></name><name><surname>Mavilio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Designing lentiviral vectors for gene therapy of genetic diseases</article-title><source>Viruses</source><volume>13</volume><elocation-id>1526</elocation-id><pub-id pub-id-type="doi">10.3390/v13081526</pub-id><pub-id pub-id-type="pmid">34452394</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priem</surname><given-names>B</given-names></name><name><surname>van Leent</surname><given-names>MMT</given-names></name><name><surname>Teunissen</surname><given-names>AJP</given-names></name><name><surname>Sofias</surname><given-names>AM</given-names></name><name><surname>Mourits</surname><given-names>VP</given-names></name><name><surname>Willemsen</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>ED</given-names></name><name><surname>Oosterwijk</surname><given-names>RS</given-names></name><name><surname>Meerwaldt</surname><given-names>AE</given-names></name><name><surname>Munitz</surname><given-names>J</given-names></name><name><surname>Prévot</surname><given-names>G</given-names></name><name><surname>Vera Verschuur</surname><given-names>A</given-names></name><name><surname>Nauta</surname><given-names>SA</given-names></name><name><surname>van Leeuwen</surname><given-names>EM</given-names></name><name><surname>Fisher</surname><given-names>EL</given-names></name><name><surname>de Jong</surname><given-names>KAM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Toner</surname><given-names>YC</given-names></name><name><surname>Soultanidis</surname><given-names>G</given-names></name><name><surname>Calcagno</surname><given-names>C</given-names></name><name><surname>Bomans</surname><given-names>PHH</given-names></name><name><surname>Friedrich</surname><given-names>H</given-names></name><name><surname>Sommerdijk</surname><given-names>N</given-names></name><name><surname>Reiner</surname><given-names>T</given-names></name><name><surname>Duivenvoorden</surname><given-names>R</given-names></name><name><surname>Zupančič</surname><given-names>E</given-names></name><name><surname>Di Martino</surname><given-names>JS</given-names></name><name><surname>Kluza</surname><given-names>E</given-names></name><name><surname>Rashidian</surname><given-names>M</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Dijkhuizen</surname><given-names>RM</given-names></name><name><surname>Hak</surname><given-names>S</given-names></name><name><surname>Pérez-Medina</surname><given-names>C</given-names></name><name><surname>Bravo-Cordero</surname><given-names>JJ</given-names></name><name><surname>de Winther</surname><given-names>MPJ</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van Elsas</surname><given-names>A</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Rialdi</surname><given-names>A</given-names></name><name><surname>Torre</surname><given-names>D</given-names></name><name><surname>Guccione</surname><given-names>E</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Griffioen</surname><given-names>AW</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition</article-title><source>Cell</source><volume>183</volume><fpage>786</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.059</pub-id><pub-id pub-id-type="pmid">33125893</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Pulido</surname><given-names>JIR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Evaluation of Clinical and Radiographic Parameters in Bony Defects Treated With Recombinant Human Platelet-Derived Growth Factor in Combination With Allograft</article-title><source>Clinicaltrials.Gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06162832">https://clinicaltrials.gov/study/NCT06162832</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib155"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Quanta Medical</collab></person-group><year iso-8601-date="2025">2025</year><article-title>First-in-Human Study of MATTISSE Tissue Engineering Chamber in Adult Female After Total Mastectomy for Breast Cancer in Immediate or Delayed 2-Stage Tissue Expander Reconstruction or Conversion from Implant-Based to Autologous Reconstruction</article-title><source>Clinicaltrials.Gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05460780">https://clinicaltrials.gov/study/NCT05460780</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib156"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Radboud University Medical Center</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Trained Immunity of Myeloid Cells and Their 1270 Progenitors in Patients With Non-Medullary Thyroid Carcinoma and Colon Carcinoma</article-title><source>Clinicaltrials.Gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05280379">https://clinicaltrials.gov/study/NCT05280379</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib157"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Radboud University Medical Center</collab></person-group><year iso-8601-date="2024">2024</year><article-title>HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies</article-title><source>Clinicaltrials.Gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06444607">https://clinicaltrials.gov/study/NCT06444607</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramey-Ward</surname><given-names>AN</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ogasawara</surname><given-names>H</given-names></name><name><surname>Bremer-Sai</surname><given-names>EC</given-names></name><name><surname>Brazhkina</surname><given-names>O</given-names></name><name><surname>Franck</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Salaita</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Optomechanically actuated hydrogel platform for cell stimulation with spatial and temporal resolution</article-title><source>ACS Biomaterials Science &amp; Engineering</source><volume>9</volume><fpage>5361</fpage><lpage>5375</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.3c00516</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiss</surname><given-names>KA</given-names></name><name><surname>Angelos</surname><given-names>MG</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Pohlmann</surname><given-names>PR</given-names></name><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Chao</surname><given-names>J</given-names></name><name><surname>Shestova</surname><given-names>O</given-names></name><name><surname>Serody</surname><given-names>JS</given-names></name><name><surname>Schmierer</surname><given-names>M</given-names></name><name><surname>Kremp</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>M</given-names></name><name><surname>Qureshi</surname><given-names>R</given-names></name><name><surname>Schott</surname><given-names>BH</given-names></name><name><surname>Sonawane</surname><given-names>P</given-names></name><name><surname>DeLong</surname><given-names>SC</given-names></name><name><surname>Christiano</surname><given-names>M</given-names></name><name><surname>Swaby</surname><given-names>RF</given-names></name><name><surname>Abramson</surname><given-names>S</given-names></name><name><surname>Locke</surname><given-names>K</given-names></name><name><surname>Barton</surname><given-names>D</given-names></name><name><surname>Kennedy</surname><given-names>E</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Cushing</surname><given-names>D</given-names></name><name><surname>Klichinsky</surname><given-names>M</given-names></name><name><surname>Condamine</surname><given-names>T</given-names></name><name><surname>Abdou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial</article-title><source>Nature Medicine</source><volume>31</volume><fpage>1171</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1038/s41591-025-03495-z</pub-id><pub-id pub-id-type="pmid">39920391</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunometabolic control of trained immunity</article-title><source>Molecular Aspects of Medicine</source><volume>77</volume><elocation-id>100897</elocation-id><pub-id pub-id-type="doi">10.1016/j.mam.2020.100897</pub-id><pub-id pub-id-type="pmid">32891423</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>LA</given-names></name><name><surname>Sethna</surname><given-names>Z</given-names></name><name><surname>Soares</surname><given-names>KC</given-names></name><name><surname>Olcese</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>N</given-names></name><name><surname>Patterson</surname><given-names>E</given-names></name><name><surname>Lihm</surname><given-names>J</given-names></name><name><surname>Ceglia</surname><given-names>N</given-names></name><name><surname>Guasp</surname><given-names>P</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Chandra</surname><given-names>AK</given-names></name><name><surname>Waters</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Amisaki</surname><given-names>M</given-names></name><name><surname>Zebboudj</surname><given-names>A</given-names></name><name><surname>Odgerel</surname><given-names>Z</given-names></name><name><surname>Payne</surname><given-names>G</given-names></name><name><surname>Derhovanessian</surname><given-names>E</given-names></name><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Rhee</surname><given-names>I</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Dobrin</surname><given-names>A</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Łuksza</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Basturk</surname><given-names>O</given-names></name><name><surname>Gönen</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Do</surname><given-names>RK</given-names></name><name><surname>Epstein</surname><given-names>AS</given-names></name><name><surname>Momtaz</surname><given-names>P</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Sugarman</surname><given-names>R</given-names></name><name><surname>Varghese</surname><given-names>AM</given-names></name><name><surname>Won</surname><given-names>E</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>AC</given-names></name><name><surname>D’Angelica</surname><given-names>MI</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Greenbaum</surname><given-names>BD</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>Drebin</surname><given-names>J</given-names></name><name><surname>O’Reilly</surname><given-names>EM</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><volume>618</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblum</surname><given-names>D</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Epithelial-immune crosstalk in health and disease</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>74</volume><elocation-id>101910</elocation-id><pub-id pub-id-type="doi">10.1016/j.gde.2022.101910</pub-id><pub-id pub-id-type="pmid">35461159</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>SK</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name><name><surname>Olson</surname><given-names>BS</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>O’Brien</surname><given-names>VP</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Livny</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Roberson</surname><given-names>EDO</given-names></name><name><surname>Bomjan</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Sha</surname><given-names>M</given-names></name><name><surname>Estfanous</surname><given-names>S</given-names></name><name><surname>Amer</surname><given-names>AO</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Stappenbeck</surname><given-names>TS</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Hannan</surname><given-names>TJ</given-names></name><name><surname>Hultgren</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Uropathogenic <italic>Escherichia coli</italic> infection-induced epithelial trained immunity impacts urinary tract disease outcome</article-title><source>Nature Microbiology</source><volume>8</volume><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1038/s41564-023-01346-6</pub-id><pub-id pub-id-type="pmid">37037942</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Kerstens</surname><given-names>HHD</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Matarese</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Ratter</surname><given-names>J</given-names></name><name><surname>Berentsen</surname><given-names>K</given-names></name><name><surname>van der Ent</surname><given-names>MA</given-names></name><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Janssen-Megens</surname><given-names>EM</given-names></name><name><surname>Ter Huurne</surname><given-names>M</given-names></name><name><surname>Mandoli</surname><given-names>A</given-names></name><name><surname>van Schaik</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Burden</surname><given-names>F</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Frontini</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1251086</elocation-id><pub-id pub-id-type="doi">10.1126/science.1251086</pub-id><pub-id pub-id-type="pmid">25258085</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safari</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>WJ</given-names></name><name><surname>Saito</surname><given-names>E</given-names></name><name><surname>Kaczorowski</surname><given-names>N</given-names></name><name><surname>Carethers</surname><given-names>L</given-names></name><name><surname>Shea</surname><given-names>LD</given-names></name><name><surname>Eniola-Adefeso</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neutrophils preferentially phagocytose elongated particles-An opportunity for selective targeting in acute inflammatory diseases</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaba1474</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba1474</pub-id><pub-id pub-id-type="pmid">32577517</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Oehm</surname><given-names>P</given-names></name><name><surname>Derhovanessian</surname><given-names>E</given-names></name><name><surname>Jabulowsky</surname><given-names>RA</given-names></name><name><surname>Vormehr</surname><given-names>M</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Maurus</surname><given-names>D</given-names></name><name><surname>Schwarck-Kokarakis</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>AN</given-names></name><name><surname>Omokoko</surname><given-names>T</given-names></name><name><surname>Kranz</surname><given-names>LM</given-names></name><name><surname>Diken</surname><given-names>M</given-names></name><name><surname>Kreiter</surname><given-names>S</given-names></name><name><surname>Haas</surname><given-names>H</given-names></name><name><surname>Attig</surname><given-names>S</given-names></name><name><surname>Rae</surname><given-names>R</given-names></name><name><surname>Cuk</surname><given-names>K</given-names></name><name><surname>Kemmer-Brück</surname><given-names>A</given-names></name><name><surname>Breitkreuz</surname><given-names>A</given-names></name><name><surname>Tolliver</surname><given-names>C</given-names></name><name><surname>Caspar</surname><given-names>J</given-names></name><name><surname>Quinkhardt</surname><given-names>J</given-names></name><name><surname>Hebich</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>M</given-names></name><name><surname>Hohberger</surname><given-names>A</given-names></name><name><surname>Vogler</surname><given-names>I</given-names></name><name><surname>Liebig</surname><given-names>I</given-names></name><name><surname>Renken</surname><given-names>S</given-names></name><name><surname>Sikorski</surname><given-names>J</given-names></name><name><surname>Leierer</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>V</given-names></name><name><surname>Mitzel-Rink</surname><given-names>H</given-names></name><name><surname>Miederer</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Grabbe</surname><given-names>S</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Pinter</surname><given-names>A</given-names></name><name><surname>Kaufmann</surname><given-names>R</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma</article-title><source>Nature</source><volume>585</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2537-9</pub-id><pub-id pub-id-type="pmid">32728218</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>TM</given-names></name><name><surname>Desouza</surname><given-names>K</given-names></name><name><surname>Fahey</surname><given-names>JV</given-names></name><name><surname>Beagley</surname><given-names>KW</given-names></name><name><surname>Wira</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells</article-title><source>Immunology</source><volume>112</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.01898.x</pub-id><pub-id pub-id-type="pmid">15196211</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrijver</surname><given-names>DP</given-names></name><name><surname>Röring</surname><given-names>RJ</given-names></name><name><surname>Deckers</surname><given-names>J</given-names></name><name><surname>de Dreu</surname><given-names>A</given-names></name><name><surname>Toner</surname><given-names>YC</given-names></name><name><surname>Prevot</surname><given-names>G</given-names></name><name><surname>Priem</surname><given-names>B</given-names></name><name><surname>Munitz</surname><given-names>J</given-names></name><name><surname>Nugraha</surname><given-names>EG</given-names></name><name><surname>van Elsas</surname><given-names>Y</given-names></name><name><surname>Azzun</surname><given-names>A</given-names></name><name><surname>Anbergen</surname><given-names>T</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Becker</surname><given-names>AMD</given-names></name><name><surname>Pérez-Medina</surname><given-names>C</given-names></name><name><surname>Oosterwijk</surname><given-names>RS</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Jansen</surname><given-names>A</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Kox</surname><given-names>M</given-names></name><name><surname>Beldman</surname><given-names>TJ</given-names></name><name><surname>Kluza</surname><given-names>E</given-names></name><name><surname>van Leent</surname><given-names>MMT</given-names></name><name><surname>Teunissen</surname><given-names>AJP</given-names></name><name><surname>van der Meel</surname><given-names>R</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Merkx</surname><given-names>M</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells</article-title><source>Nature Biomedical Engineering</source><volume>7</volume><fpage>1097</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s41551-023-01050-0</pub-id><pub-id pub-id-type="pmid">37291433</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>AK</given-names></name><name><surname>Casas</surname><given-names>E</given-names></name><name><surname>Schneider</surname><given-names>SE</given-names></name><name><surname>Swearingen</surname><given-names>AR</given-names></name><name><surname>Van Den Elzen</surname><given-names>CL</given-names></name><name><surname>Seelbinder</surname><given-names>B</given-names></name><name><surname>Barthold</surname><given-names>JE</given-names></name><name><surname>Kugel</surname><given-names>JF</given-names></name><name><surname>Stern</surname><given-names>JL</given-names></name><name><surname>Foster</surname><given-names>KJ</given-names></name><name><surname>Emery</surname><given-names>NC</given-names></name><name><surname>Brumbaugh</surname><given-names>J</given-names></name><name><surname>Neu</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mechanical memory stored through epigenetic remodeling reduces cell therapeutic potential</article-title><source>Biophysical Journal</source><volume>122</volume><fpage>1428</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2023.03.004</pub-id><pub-id pub-id-type="pmid">36871159</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Targeted delivery of nano-radiosensitizers for tumor radiotherapy</article-title><source>Coordination Chemistry Reviews</source><volume>518</volume><elocation-id>216101</elocation-id><pub-id pub-id-type="doi">10.1016/j.ccr.2024.216101</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slezak</surname><given-names>AJ</given-names></name><name><surname>Mansurov</surname><given-names>A</given-names></name><name><surname>Raczy</surname><given-names>MM</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Alpar</surname><given-names>AT</given-names></name><name><surname>Lauterbach</surname><given-names>AL</given-names></name><name><surname>Wallace</surname><given-names>RP</given-names></name><name><surname>Weathered</surname><given-names>RK</given-names></name><name><surname>Medellin</surname><given-names>JEG</given-names></name><name><surname>Battistella</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>LT</given-names></name><name><surname>Marchell</surname><given-names>TM</given-names></name><name><surname>Gomes</surname><given-names>S</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tumor cell-surface binding of immune stimulating polymeric glyco-adjuvant via cysteine-reactive pyridyl disulfide promotes antitumor immunity</article-title><source>ACS Central Science</source><volume>8</volume><fpage>1435</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.2c00704</pub-id><pub-id pub-id-type="pmid">36313164</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soltani</surname><given-names>L</given-names></name><name><surname>Varmira</surname><given-names>K</given-names></name><name><surname>Nazari</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Comparison of the differentiation of ovine fetal bone-marrow mesenchymal stem cells towards osteocytes on chitosan/alginate/CuO-NPs and chitosan/alginate/FeO-NPs scaffolds</article-title><source>Scientific Reports</source><volume>14</volume><elocation-id>161</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-50664-6</pub-id><pub-id pub-id-type="pmid">38168144</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SY</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Hoffman</surname><given-names>T</given-names></name><name><surname>Akhtar</surname><given-names>N</given-names></name><name><surname>Norris</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kelkhoff</surname><given-names>DO</given-names></name><name><surname>Ang</surname><given-names>CE</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Kasko</surname><given-names>A</given-names></name><name><surname>Downing</surname><given-names>TL</given-names></name><name><surname>Poo</surname><given-names>M-M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Biphasic regulation of epigenetic state by matrix stiffness during cell reprogramming</article-title><source>Science Advances</source><volume>10</volume><elocation-id>eadk0639</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adk0639</pub-id><pub-id pub-id-type="pmid">38354231</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souto</surname><given-names>EB</given-names></name><name><surname>Fangueiro</surname><given-names>JF</given-names></name><name><surname>Fernandes</surname><given-names>AR</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>Sanchez-Lopez</surname><given-names>E</given-names></name><name><surname>Garcia</surname><given-names>ML</given-names></name><name><surname>Severino</surname><given-names>P</given-names></name><name><surname>Paganelli</surname><given-names>MO</given-names></name><name><surname>Chaud</surname><given-names>MV</given-names></name><name><surname>Silva</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery</article-title><source>Heliyon</source><volume>8</volume><elocation-id>e08938</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e08938</pub-id><pub-id pub-id-type="pmid">35198788</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Sheng</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Ping</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>5659</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-50093-7</pub-id><pub-id pub-id-type="pmid">38969646</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subudhi</surname><given-names>I</given-names></name><name><surname>Konieczny</surname><given-names>P</given-names></name><name><surname>Prystupa</surname><given-names>A</given-names></name><name><surname>Castillo</surname><given-names>RL</given-names></name><name><surname>Sze-Tu</surname><given-names>E</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Rosenblum</surname><given-names>D</given-names></name><name><surname>Reznikov</surname><given-names>I</given-names></name><name><surname>Sidhu</surname><given-names>I</given-names></name><name><surname>Loomis</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>CP</given-names></name><name><surname>Anandasabapathy</surname><given-names>N</given-names></name><name><surname>Suárez-Fariñas</surname><given-names>M</given-names></name><name><surname>Gudjonsson</surname><given-names>JE</given-names></name><name><surname>Tsirigos</surname><given-names>A</given-names></name><name><surname>Scher</surname><given-names>JU</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation</article-title><source>Immunity</source><volume>57</volume><fpage>1665</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.04.022</pub-id><pub-id pub-id-type="pmid">38772365</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Mohagheghian</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Force-induced gene up-regulation does not follow the weak power law but depends on H3K9 demethylation</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaay9095</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aay9095</pub-id><pub-id pub-id-type="pmid">32270037</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajik</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcription upregulation via force-induced direct stretching of chromatin</article-title><source>Nature Materials</source><volume>15</volume><fpage>1287</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1038/nmat4729</pub-id><pub-id pub-id-type="pmid">27548707</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Ip</surname><given-names>CKM</given-names></name><name><surname>Bahmani</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Rosenberger</surname><given-names>MG</given-names></name><name><surname>Esser-Kahn</surname><given-names>AP</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Data-driven discovery of innate immunomodulators <italic>via</italic> machine learning-guided high throughput screening</article-title><source>Chemical Science</source><volume>14</volume><fpage>12747</fpage><lpage>12766</lpage><pub-id pub-id-type="doi">10.1039/d3sc03613h</pub-id><pub-id pub-id-type="pmid">38020385</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarancón</surname><given-names>R</given-names></name><name><surname>Domínguez-Andrés</surname><given-names>J</given-names></name><name><surname>Uranga</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>AV</given-names></name><name><surname>Groh</surname><given-names>LA</given-names></name><name><surname>Domenech</surname><given-names>M</given-names></name><name><surname>González-Camacho</surname><given-names>F</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name><name><surname>Aguilo</surname><given-names>N</given-names></name><name><surname>Yuste</surname><given-names>J</given-names></name><name><surname>Martín</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008404</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008404</pub-id><pub-id pub-id-type="pmid">32240273</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaxton</surname><given-names>CS</given-names></name><name><surname>Rink</surname><given-names>JS</given-names></name><name><surname>Naha</surname><given-names>PC</given-names></name><name><surname>Cormode</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lipoproteins and lipoprotein mimetics for imaging and drug delivery</article-title><source>Advanced Drug Delivery Reviews</source><volume>106</volume><fpage>116</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.04.020</pub-id><pub-id pub-id-type="pmid">27133387</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Therapeutics</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors</article-title><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06375187">https://clinicaltrials.gov/study/NCT06375187</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Nice</surname><given-names>EC</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies</article-title><source>Journal of Hematology &amp; Oncology</source><volume>15</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-022-01320-5</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Hui</surname><given-names>H</given-names></name><name><surname>Shang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles</article-title><source>Theranostics</source><volume>11</volume><fpage>506</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.7150/thno.49812</pub-id><pub-id pub-id-type="pmid">33391489</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Too</surname><given-names>NSH</given-names></name><name><surname>Ho</surname><given-names>NCW</given-names></name><name><surname>Adine</surname><given-names>C</given-names></name><name><surname>Iyer</surname><given-names>NG</given-names></name><name><surname>Fong</surname><given-names>ELS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hot or cold: bioengineering immune contextures into in vitro patient-derived tumor models</article-title><source>Advanced Drug Delivery Reviews</source><volume>175</volume><elocation-id>113791</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.05.001</pub-id><pub-id pub-id-type="pmid">33965462</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Shah</surname><given-names>SS</given-names></name><name><surname>Ko</surname><given-names>C-W</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Morrison</surname><given-names>MS</given-names></name><name><surname>Giancarlo</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>RN</given-names></name><name><surname>Hildebrand</surname><given-names>EM</given-names></name><name><surname>Voytek</surname><given-names>SB</given-names></name><name><surname>El Sebae</surname><given-names>GK</given-names></name><name><surname>Wright</surname><given-names>SH</given-names></name><name><surname>Lofgren</surname><given-names>L</given-names></name><name><surname>Clarkson</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>C</given-names></name><name><surname>Linder</surname><given-names>SJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Eom</surname><given-names>T</given-names></name><name><surname>Parikh</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>Y</given-names></name><name><surname>Martinez</surname><given-names>S</given-names></name><name><surname>Malyala</surname><given-names>P</given-names></name><name><surname>Abubucker</surname><given-names>S</given-names></name><name><surname>Friedland</surname><given-names>AE</given-names></name><name><surname>Maeder</surname><given-names>ML</given-names></name><name><surname>Lombardo</surname><given-names>A</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Jaffe</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels</article-title><source>Nature Medicine</source><volume>31</volume><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1038/s41591-025-03508-x</pub-id><pub-id pub-id-type="pmid">39930141</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhl</surname><given-names>P</given-names></name><name><surname>Sauter</surname><given-names>M</given-names></name><name><surname>Hertlein</surname><given-names>T</given-names></name><name><surname>Witzigmann</surname><given-names>D</given-names></name><name><surname>Laffleur</surname><given-names>F</given-names></name><name><surname>Hofhaus</surname><given-names>G</given-names></name><name><surname>Fidelj</surname><given-names>V</given-names></name><name><surname>Tursch</surname><given-names>A</given-names></name><name><surname>Özbek</surname><given-names>S</given-names></name><name><surname>Hopke</surname><given-names>E</given-names></name><name><surname>Haberkorn</surname><given-names>U</given-names></name><name><surname>Bernkop‐Schnürch</surname><given-names>A</given-names></name><name><surname>Ohlsen</surname><given-names>K</given-names></name><name><surname>Fricker</surname><given-names>G</given-names></name><name><surname>Mier</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Overcoming the mucosal barrier: tetraether lipid‐stabilized liposomal nanocarriers decorated with cell‐penetrating peptides enable oral delivery of vancomycin</article-title><source>Advanced Therapeutics</source><volume>4</volume><elocation-id>2000247</elocation-id><pub-id pub-id-type="doi">10.1002/adtp.202000247</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="web"><person-group person-group-type="author"><collab>University Hospital, Basel, Switzerland</collab></person-group><year iso-8601-date="2025">2025</year><article-title>Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-Based Engineered Cartilage Implantation in a Randomized, Controlled, Multi-Center Phase II Clinical Trial</article-title><source>Clinicaltrials.Gov</source><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06163573">https://clinicaltrials.gov/study/NCT06163573</ext-link><date-in-citation iso-8601-date="2025-05-15">May 15, 2025</date-in-citation></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>CDCC</given-names></name><name><surname>Groh</surname><given-names>L</given-names></name><name><surname>Keating</surname><given-names>ST</given-names></name><name><surname>Kaffa</surname><given-names>C</given-names></name><name><surname>Noz</surname><given-names>MP</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>van Herwaarden</surname><given-names>AE</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Timmers</surname><given-names>HJLM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Riksen</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Catecholamines induce trained immunity in monocytes in vitro and in vivo</article-title><source>Circulation Research</source><volume>127</volume><fpage>269</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315800</pub-id><pub-id pub-id-type="pmid">32241223</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walk</surname><given-names>J</given-names></name><name><surname>de Bree</surname><given-names>LCJ</given-names></name><name><surname>Graumans</surname><given-names>W</given-names></name><name><surname>Stoter</surname><given-names>R</given-names></name><name><surname>van Gemert</surname><given-names>G-J</given-names></name><name><surname>van de Vegte-Bolmer</surname><given-names>M</given-names></name><name><surname>Teelen</surname><given-names>K</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Behet</surname><given-names>MC</given-names></name><name><surname>Keramati</surname><given-names>F</given-names></name><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Yang</surname><given-names>ASP</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>de Mast</surname><given-names>Q</given-names></name><name><surname>van der Ven</surname><given-names>AJAM</given-names></name><name><surname>Stabell Benn</surname><given-names>C</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Outcomes of controlled human malaria infection after BCG vaccination</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>874</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08659-3</pub-id><pub-id pub-id-type="pmid">30787276</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Programmed biomolecule delivery orchestrate bone tissue regeneration via MSC recruitment and epigenetic modulation</article-title><source>Chemical Engineering Journal</source><volume>438</volume><elocation-id>135518</elocation-id><pub-id pub-id-type="doi">10.1016/j.cej.2022.135518</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Wipf</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>XQ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targethunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database</article-title><source>The AAPS Journal</source><volume>15</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9449-z</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Stem cell therapy for Crohn’s disease: systematic review and meta-analysis of preclinical and clinical studies</article-title><source>Stem Cell Research &amp; Therapy</source><volume>12</volume><elocation-id>463</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-021-02533-0</pub-id><pub-id pub-id-type="pmid">34407875</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Bashir</surname><given-names>MEH</given-names></name><name><surname>Hesser</surname><given-names>LA</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>SMC</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Culleen</surname><given-names>E</given-names></name><name><surname>Sabados</surname><given-names>M</given-names></name><name><surname>Dylla</surname><given-names>NP</given-names></name><name><surname>Campbell</surname><given-names>E</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Nonnecke</surname><given-names>EB</given-names></name><name><surname>Bevins</surname><given-names>CL</given-names></name><name><surname>Wilson</surname><given-names>DS</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name><name><surname>Nagler</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Treatment of peanut allergy and colitis in mice via the intestinal release of butyrate from polymeric micelles</article-title><source>Nature Biomedical Engineering</source><volume>7</volume><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/s41551-022-00972-5</pub-id><pub-id pub-id-type="pmid">36550307</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Basak</surname><given-names>P</given-names></name><name><surname>Siegwart</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery</article-title><source>Nature Protocols</source><volume>18</volume><fpage>265</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00755-x</pub-id><pub-id pub-id-type="pmid">36316378</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Tissue-resident trained immunity in hepatocytes protects against septic liver injury in zebrafish</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>114324</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114324</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>DN</given-names></name><name><surname>Tardi</surname><given-names>PG</given-names></name><name><surname>Mayer</surname><given-names>LD</given-names></name><name><surname>Bally</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles</article-title><source>Drug Safety</source><volume>24</volume><fpage>903</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.2165/00002018-200124120-00004</pub-id><pub-id pub-id-type="pmid">11735647</pub-id></element-citation></ref><ref id="bib198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>AK</given-names></name><name><surname>Barnett</surname><given-names>HH</given-names></name><name><surname>Caldorera-Moore</surname><given-names>ME</given-names></name><name><surname>Newman</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Poly (ethylene glycol) hydrogel elasticity influences human mesenchymal stem cell behavior</article-title><source>Regenerative Biomaterials</source><volume>5</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1093/rb/rby008</pub-id><pub-id pub-id-type="pmid">29942649</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wimmers</surname><given-names>F</given-names></name><name><surname>Donato</surname><given-names>M</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Ashuach</surname><given-names>T</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Dvorak</surname><given-names>M</given-names></name><name><surname>Foecke</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>SE</given-names></name><name><surname>Hagan</surname><given-names>T</given-names></name><name><surname>De Jong</surname><given-names>SE</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>van der Most</surname><given-names>R</given-names></name><name><surname>Cheung</surname><given-names>P</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Bosinger</surname><given-names>SE</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Utz</surname><given-names>PJ</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination</article-title><source>Cell</source><volume>184</volume><fpage>3915</fpage><lpage>3935</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.05.039</pub-id><pub-id pub-id-type="pmid">34174187</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>MA</given-names></name><name><surname>Modzelewska</surname><given-names>K</given-names></name><name><surname>Kwong</surname><given-names>L</given-names></name><name><surname>Keely</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Focal adhesion regulation of cell behavior</article-title><source>Biochimica et Biophysica Acta</source><volume>1692</volume><fpage>103</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2004.04.007</pub-id><pub-id pub-id-type="pmid">15246682</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Regulation of macrophage behavior by chitosan scaffolds with different elastic modulus</article-title><source>Coatings</source><volume>12</volume><elocation-id>1742</elocation-id><pub-id pub-id-type="doi">10.3390/coatings12111742</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Edahiro</surname><given-names>R</given-names></name><name><surname>Søndergaard</surname><given-names>JN</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Amiya</surname><given-names>S</given-names></name><name><surname>Nameki</surname><given-names>S</given-names></name><name><surname>Yoshimine</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Takeshima</surname><given-names>Y</given-names></name><name><surname>Sakakibara</surname><given-names>S</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Motooka</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y-C</given-names></name><name><surname>Shirai</surname><given-names>Y</given-names></name><name><surname>Okita</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>J</given-names></name><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Wing</surname><given-names>JB</given-names></name><name><surname>Okuzaki</surname><given-names>D</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Kumanogoh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e163347</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.163347</pub-id><pub-id pub-id-type="pmid">36282593</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SQ</given-names></name><name><surname>Zhang</surname><given-names>LX</given-names></name><name><surname>Ge</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>JW</given-names></name><name><surname>Hu</surname><given-names>JX</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Lu</surname><given-names>AP</given-names></name><name><surname>Hou</surname><given-names>TJ</given-names></name><name><surname>Cao</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>In-silico target prediction by ensemble chemogenomic model based on multi-scale information of chemical structures and protein sequences</article-title><source>Journal of Cheminformatics</source><volume>15</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-023-00720-0</pub-id><pub-id pub-id-type="pmid">37088813</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Haddadi</surname><given-names>S</given-names></name><name><surname>Barra</surname><given-names>NG</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Damjanovic</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>R</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dvorkin-Gheva</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Schertzer</surname><given-names>JD</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Induction of autonomous memory alveolar macrophages requires T Cell Help and Is Critical to Trained Immunity</article-title><source>Cell</source><volume>175</volume><fpage>1634</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.042</pub-id><pub-id pub-id-type="pmid">30433869</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahedi Tehrani</surname><given-names>T</given-names></name><name><surname>Irani</surname><given-names>S</given-names></name><name><surname>Ardeshirylajimi</surname><given-names>A</given-names></name><name><surname>Seyedjafari</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Natural based hydrogels promote chondrogenic differentiation of human mesenchymal stem cells</article-title><source>Frontiers in Bioengineering and Biotechnology</source><volume>12</volume><elocation-id>1363241</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2024.1363241</pub-id><pub-id pub-id-type="pmid">38567084</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Moorlag</surname><given-names>SJ</given-names></name><name><surname>Dominguez-Andres</surname><given-names>J</given-names></name><name><surname>Bulut</surname><given-names>Ö</given-names></name><name><surname>Kilic</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>C-J</given-names></name><name><surname>Joosten</surname><given-names>LA</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell RNA sequencing reveals induction of distinct trained-immunity programs in human monocytes</article-title><source>The Journal of Clinical Investigation</source><volume>132</volume><elocation-id>e147719</elocation-id><pub-id pub-id-type="doi">10.1172/JCI147719</pub-id><pub-id pub-id-type="pmid">35133977</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Stem cell-derived exosome versus stem cell therapy</article-title><source>Nature Reviews Bioengineering</source><volume>1</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1038/s44222-023-00064-2</pub-id><pub-id pub-id-type="pmid">37359776</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X-B</given-names></name><name><surname>Chen</surname><given-names>Y-P</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhai</surname><given-names>Y-Y</given-names></name><name><surname>Sun</surname><given-names>Y-L</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>X-Q</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y-B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Extracellular matrix stiffness regulates DNA Methylation by PKCα-dependent nuclear transport of DNMT3L</article-title><source>Advanced Healthcare Materials</source><volume>10</volume><elocation-id>e2100821</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202100821</pub-id><pub-id pub-id-type="pmid">34174172</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yeh</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and Atherosclerosis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2025.01.09.632179</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2025">2025</year><source>Electrospun Biomimetic Periosteum Promotes Diabetic Bone Defect Regeneration through Regulating Macrophage Polarization and Sequential Drug Release</source><publisher-name>ACS Biomater Sci Eng</publisher-name><pub-id pub-id-type="doi">10.1021/acsbiomaterials.4c02095</pub-id></element-citation></ref><ref id="bib211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziogas</surname><given-names>A</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Trained immunity-related vaccines: innate immune memory and heterologous protection against infections</article-title><source>Trends in Molecular Medicine</source><volume>28</volume><fpage>497</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2022.03.009</pub-id><pub-id pub-id-type="pmid">35466062</pub-id></element-citation></ref></ref-list></back></article>